Faculty Collaboration Database

1. SCHULTZ CJ, Geard CR: Radioresponse of Human Glial Tumors Across Grade as Function of Acute and Chronic Irradiation. Int J Rad Onco Biol Phys 19: 1397-1403, 1990. (Cited in the 1992 Year Book of Neurology and Neurosurgery as one of the ten most important papers of that year.)

2. Kelly JC, Wasserman DG, Bernard WD, SCHULTZ CJ, Knapp JF: Chloroquine Poisoning in a Child. Ann Emerg Med 19: 47-50 January 1990.

3. Jacobs JP, Murray KJ, SCHULTZ CJ, Wilson JF, Goswitz MS, Stevens CW, Cox JD: Central Lymphatic Irradiation for Stage III Nodular Malignant Lymphoma: Long-term Results. J Clin Oncol 11: 233-238, 1993.

4. Larson DA, Bova F, Eisert D, Kline R, Loeffler J, Lutz W, Mehta M, Palta J, Schewe K, SCHULTZ C, Shaw E, Wilson JF: Current Radiosurgery Practice: Results of an ASTRO Survey. Int J Radiat Oncol Biol Phys 28: 523-526, 1994.

5. Larson DA, Bova F, Eisert D, Kline R, Loeffler J, Lutz W, Mehta M, Palta J, Schewe K, SCHULTZ C, Shaw E, Wilson F, Lunsford LD, Alexander E, Chapman P, Coffey R, Friedman W, Harsh IV G, Maciunas R, Olivíer A, Steinberg G, Walsh J: Consensus Statement on Stereotactic Radiosurgery Quality Improvement. Int J Radiat Oncol Biol Phys 28: 527-530,1994.

6. Lunsford LD, Alexander E, Bucholz R, Chapman P, Coffey R, Friedman W, Harsh IV G, Maciunas R, Olivier A, Steinberg G, Walsh J, Larson DA, Bova F, Eisert D, Kline R, Loeffler J, Lutz W, Mehta M, Palta J, Schewe K, SCHULTZ C, Shaw E, Wilson F: Consensus Statement on Stereotactic Radiosurgery: Quality Improvement. Neurosurg 34:193-195, 1994.

7. Rock DB, SCHULTZ CJ, Murray KJ, Wilson JF, Cox JD: Continuous split course irradiation for Stage I and II Hodgkin's Disease: 20 Year Experience at the Medical College of Wisconsin. Radiother Oncol 30: 222-226, 1994.

8. SCHULTZ CJ, Gaffney DK, Lindstrom MJ, Kinsella TJ: Iododeoxyuridine radiosensitization of human glioblastoma cells exposed to acute and chronic gamma irradiation: Mechanistic implications and clinical relevance. The Cancer Journal 1: 151-162, 1995.

9. Andryk J, Freije JE, SCHULTZ CJ, Campbell BH, Komorowski RA: Lymphoepithelioma of the Larynx. Am J Otolaryngol 17:61-63, 1996.

10. Shaw E, Scott C, Souhami L, Dinapoli R, Bahary J-P, Kline R, Wharam M, SCHULTZ C, Davey P, Loeffler J, Del Rowe J, Marks L, Fisher B, Shin K: Radiosurgery for the treatment of previously irradiated recurrent primary brain tumors and brain metastases: Initial Report of Radiation Therapy Oncology Group Protocol 90-05. Int J Radiat Oncol Biol Phys, 34: 647-654, 1996.

11. SCHULTZ C, Scott C, Sherman W, Donahue B, Fields J, Murray K, Fisher B, Abrams R, Meis-Kindblom, J: Pre-irradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary central nervous system lymphomas: Initial Report of Radiation Therapy Oncology Group (RTOG) protocol 88-06. J Clin Oncol, 14:556-564, 1996.

12. Auchter RM, Lamond JP, Alexander E, Buatti JM, Chappell RJ, Friedman W, Kinsella TJ, Levin AB, Noyes WR, SCHULTZ C, Loeffler JS, Mehta MP: A multi-institutional outcome and prognostic factor analysis of radiosurgery for resectable single brain metastasis. (Awarded the ASTRO Resident Essay Award, 1995.)Int J Radiat Oncol Biol Phys, 35:27-35, 1996.

13. Hung RT, Jindal JR, Clowry LJ, SCHULTZ C, Freije, JE: Giant cell carcinoma of the parotid gland. Otolaryngol Head Neck Surg, 114:657-660, 1996.

14. Freije JE, Beatty TW, Campbell BH, Woodson BT, SCHULTZ CJ, Toohill RJ: Carcinoma of the larynx in patients with gastroesophageal reflux. Am J Otolaryngol, 17:386-390, 1996.

15. Campbell BH, Mark DH, Soneson E, Freije JE, SCHULTZ CJ: The Role of Dental Prosthesis in Alveolar Ridge Squamous Carcinomas. Arch Otolaryngol, 123(10): 112-115, 1997.

16. Boyd TS, Harari PM, Voytovich MC, Hartig GK, Ford CN, Campbell BH, Foote RL, SCHULTZ CJ: Planned Post-radiotherapy Neck Dissection in Patients with Advanced Head and Neck Cancer: Head Neck 20: 132-137, 1998.

17. Adamson A, Rand S, Prost R, Kim T, SCHULTZ C, Haughton V. The Effect of Single Voxel Proton MRS on the Management of Patients with Focal Lesions of the Brain. Radiol, 209(1): 73-78, 1998.

18. Prados M, Scott C, Sandler H, Buckner J, Phillips T, SCHULTZ C, Urtasun R, Davis R, Gutin P, Cascino T, Greenberg H, Curran W. A Phase III Randomized Study of Radiotherapy with or without BudR plus Procarbazine, CCNU and Vincristine (PCV) for the Treatment of Anaplastic Astrocytoma: A Preliminary Report of RTOG 94-04. Int J Radiat Oncol Biol Phys 45(5):1109-1115, 1999.

19. Corn B, Dolinskas C, Scott C, Donahue B, SCHULTZ C, Nelson D, Fisher B. Strong Correlation between Imaging Response and Survival among Patients with Primary Central Nervous System Lymphoma. Int J Radiat Oncol Biol Phys 47(2): 299-303, 2000.

20. Spencer S, Harris J, Wheeler R, Machtay M, SCHULTZ C, Sparros W, Rothman M, Meredith R. RTOG 96-10 Phase I study of reirradiation (RRT) with concurrent Hydroxyurea (HU) and 5-Fluorouracil (FU) in patients (PTS) with squamous cell cancer of the head and neck (SCH&N). Int J Radiat Oncol Biol Phys 51(5):1299-1304, 2001.

21. Michalski, J, Purdy J, Gaspar L, Souhami L, Ballow M, Bradley J, Chao K, Crane C, Eisbruch A, Fallowil D, Forster K, Fowler J, Gillin M, Graham M, Harms W, Huq S, Kline R, Langer M, Mackie T, Mukherji S, Podgorsak E, Roach M, Ryu M, Sandler H, SCHULTZ C, Schell M, Verhey L, Vicini F, Winter K. Image-Guided Radiation Therapy Committee. Int J Radiat Oncol Biol Phys 51(3) Suppl 2: 60-65, 2001.

22. DeAngelis LM, Seifenheld WS, Schold SC, Fisher B, SCHULTZ CJ: Combination chemotherapy and radiotherapy for newly diagnosed patients with primary central nervous system lymphoma: RTOG 93-10. J Clin Oncol 20(24): 4643-4648, 2002.

23. Mehta MP, Shapiro W, Glantz MJ, Patchell RA, Weitzner MA, Meyers CA, SCHULTZ CJ, Roa W, Leibenhaut M, Ford J, Curran W, Phan S, Smith J, Miller R, Renschler M. Lead-in phase to randomized trial of Motexafin Gadolinium and whole brain radiation for patients with brain metastasis: Centralized assessment of MRI, neurocognitive, and neurologic endpoints. J Clin Oncol, 20(16): 3445-3453, 2002.

24. Jursinic P, Prost R, SCHULTZ C: A new magnetic resonance head coil and head immobilization device for gamma knife radiosurgery: An analysis of geometric distortion and signal/noise characteristics. J Neurosurg 97 (Suppl 5): 563-568, 2002.

25. Ambinder RF, Lee S, Curran WJ, Sparano JA, Krigel RL, McArthur J, SCHULTZ CJ,Freter CE, Kaplan L, VonRoenn JH. Phase II intergroup Trial of Sequential Chemotherapy and Radiotherapy for AIDS-Related Primary CNS Lymphoma. Cancer Therapy 1: 215-221, 2003.

26. Mehta MP, Rodrigus P, Terhaard CHJ, Rao A, Suh J, Roa W, Souhami L, Bezjak A, Leibenhaut M, Komaki R, SCHULTZ C, Timmerman R, Curran W, Smith J, Phan SC, Miller RA, Renschler MF. Survival and neurological outcomes in a randomized trial of motexafin gadolinium and whole brain radiation therapy in brain metastases. J Clin Oncol, 21(13): 2529-2536, 2003.

27. Chang C, Kampalath B, SCHULTZ C, Buny-Teopengco E, Logan B, Eshoa C, Dincer AP, Perskins SL. Expression pf p53 and c-Myc correlates with survival in primary CNS diffuse large B-cell lymphoma in immunocompetent individuals. Arch Pathol Lab Med 127: 208-212, 2003.

28. Liu PT. Chivers FS. Roberts CC. SCHULTZ CJ. Beauchamp CP. Imaging of osteoid osteoma with dynamic gadolinium-enhanced MR imaging. Radiol. 227(3):691-700, 2003.

29. Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, Kish JA, Kim HE, Cmelak AJ, Rotman M, Ensley JF, Chao, C, SCHULTZ C, Lee N, Fu KK, Radiation Therapy Oncology Group 9501/Intergroup. Postoperative concurrent chemotherapy and radiation therapy in high-risk squamous cell carcinoma of the head and neck. N Engl J Med 350 (19): 1937-1944, 2004.

30. Souhami L, Sieferheld W, Brachman D, Podgorsak E, Werner-Wasik M, Lustig R, SCHULTZ C, Sause W, Okenieff P, Buckner J, Zamorano L, Mehta MP, Curran W. Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: Report of RTOG 93-05 protocol. Int J Radiat Oncol Biol Phys 60(3):853-860, 2004.

31. Prados M, Seiferheld W, Sandler H, Buckner, JC, Phillips T, SCHULTZ C et al: RTOG 94-04: A phase III randomized study of radiotherapy plus Procarbazine, CCNU, and Vincristine (PCV) with or without BudR for the treatment of anaplastic astrocytoma. Int J Radiat Oncol Biol Phys 58(4):1147-1152, 2004.

32. Harris G, Woo K, SCHULTZ C, Tayanyi R, Cancel, E. Late Onset Chemosis in Patients with Head and Neck Tumors: Ophthal Plast Reconstr Surg 20 (6):436-441, 2004.

33. Zhu XR, SCHULTZ CJ, Gillin MT. Treatment Planning Quality and Delivery Efficiency for sMLC Delivered IMRT Treatment of Oropharyngeal Cancer: A Comparative Planning Study Evaluated by RTOG H-0022 Dosimetric Criteria. J Appl Clin Med Phys 5:4,80-95, 2004.

34. Jursinic P, Rickert K, Gennarelli T, SCHULTZ C. Effect of Image Uncertainty on the Dosimetry of Trigeminal Neuralgia Irradiation: Int J Radiat Oncol Biol Phys 62:5,1559-1567, 2005.

35. Fisher B, Seiferheld W, SCHULTZ C, DeAngelis L, Nelson D, Schold SC, Curran W, Mehta M: Secondary analysis of Radiation Therapy Oncology Group (RTOG) 93-10 An intergroup phase II combined modality treatment of primary central nervous system lymphoma. J Neurooncol 74(2) 201-205, 2005.

36. Robins HI, Won M, Seiferheld W, SCHULTZ C, Choucair AK, Brachman DG, Demas WF, Mehta M: A phase II trial of radiation plus high-dose tamoxifen for glioblastoma multiforme: RTOG protocol BR-0021. Neuro Oncol 8(1):47-52 Jan 2006.

37. Cardinale R, Won M, Choucari A, Gillin M, Chakravarti A, SCHULTZ C, Souhami L, Chen A, Pham H, Mehta M: A Phase II Trial of Accelerated Radiotherapy Using Weekly Stereotactic Conformal Boost for Supratentorial Glioblastoma Multiforme RTOG 0023. Int J Radiat Oncol Biol Phys 65(5) 1422-1428, 2006.

38. Gabayan A, Green S, Sanan A, Jenrette J, SCHULTZ C, Papagikos M, Tatter S, Patel A, P Amin P, Tonnesen G, Lustig L, Bastin B, Watson G, Burri S, Stea B. GliaSite® brachytherapy for treatment of recurrent malignant gliomas: a retrospective multi-institutional study: Neurosurg 58:4, 701-709, 2006.

39. Qi XS, SCHULTZ CJ, Li XA: An estimation of radiobiologic parameters from clinical outcomes for radiation treatment planning of brain tumor. Int J Radiat Oncol Biol Phy 64:5, 1570-1580, 2006.

40. Wang D, SCHULTZ C, Jursinic P, Bialkowski M, Zhu XR, Brown WD, Rand SD, Michel MA, Campbell BH, Wong S, Li XA, Wilson, JF: Initial experience of FED/PET/CT guided IMRT of head and neck carcinoma, Int J Radiat Oncol Biol Phys 65:1, 143-151, 2006.

41. Abrey AE, Ben-Porat L, Panageas K, Yahalom J, Berkey B, Curran W, SCHULTZ C, Leibel S, Nelson D, Mehta M, DeAngelis LM. Primary central nervous system lymphoma: The Memorial Sloan-Kettering Cancer Center Prognostic Model. J Clin Oncol 24:36, 5711-5715, 2006.

42. Wong SJ, SCHULTZ CJ: Never Say Never Again: Re-irradiation and Concurrent Chemotherapy American Society of Clinical Oncology Educational Book, 43rd Annual Meeting, p 339-343, Spring 2007.

43. Colman H, Berkey B, Maor M, Groves, M, SCHULTZ C, Vermeulen S, Nelson DF, Mehta MP, Yunk WK, Radiation Therapy Oncology Group. Phase II RTOG Trial of Conventional Radiation Therapy Followed by Treatment with Recombinant Interferon-B for Supratentorial Glioblastoma: Results of RTOG 9710. Int J Radiat Oncol Biol Phys 66:3, 818-824, 2006.

44. Li XA, Qi XS, Pitterle M, Kalakota K, Mueller K, Erickson BA, Wang D, SCHULTZ CJ, Firat SY, Wilson JF. Interfractional variations in patient setup and anatomic change assessed by daily computed tomography. Int J Radiat Oncol Biol Phys 68(2):581-91, 2007.

45. Cheng GP, Ahunbay E, SCHULTZ C, Li XA: Development of an inverse optimization package to plan non-uniform dose distributions based on spatially inhomogeneous radiosensitivity extracted from biological images. Med Phys 34(4)April 2007.

46. Cao M, Eshoa C, SCHULTZ C, Black J, Zu Y, Chang CC. Primary central nervous system histiocytic sarcoma with relapse to mediastinum: a case report and review of the literature. Arch Pathol Lab Med.Feb;131(2):301-5, 2007.

47. Qi XS, SCHULTZ CJ, Li XA: Possible fractionated regimens for image-guided intensity modulated radiation therapy of large arteriovenous malformations. Phys Med Biol 52 5667-5682, 2007.

48. Yang Q, Feng Y, SCHULTZ CJ, Li XA, Wu H, Wang D. Synergistic effect of 15-lipoxygenase 2 and radiation in killing head-and-neck cancer. Cancer Gene Ther. 2008 May;15(5):323-30.

49. Spencer SA, Harris J, Wheeler RH, Machtay M, SCHULTZ C, Spanos W, Rotman M, Meredith R, Ang KK. Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck. Head Neck. 2008 Mar;30(3):281-8.

50. Vernon MR, Maheshwari M, SCHULTZ CJ, Michel MA, Wong SJ, Campbell BH, Massey BL, Wilson JF, Wang D: Clinical outcomes of patients receiving integrated PET/CT-guided radiotherapy for head and neck carcinoma. Int J Radiat Oncol Biol Phys 70(3):678-84, 2008.

51. Barasch A, Brennan M, Calais G,Canty T, Elting LS, Epstein J, Feyer P, Garden A, Grunberg SM, Keefe DM, Kudrimoti M, Molassiotis A, Oster G, Raber-DDurlacher JE, SCHULTZ C, et al: Patient reported measurements of oral mucositis in head and neck cancer patients treated with radiotherapy with or without chemotherapy: demonstration of increased frequency, severity, resistance to palliation, and impact on quality of life. Cancer 113(10)2704-13, Nov 15, 2008.

52. Hartford AC, Paliska MG, Eichler T, Beyer DC, Devineni, V, Ibbott G, Kavanagh B, Kent J, Rosenthal S, SCHULTZ CJ, Tripuraneni P, Gaspar L: American Society of Therapeutic Radiation Oncologists (ASTRO) and American College of Radiology (ACR) practice guidelines for Intensity Modulated Radiation Therapy (IMRT) Int J Radiat Oncol Biol Phys, 73(1) 9-14, 2009.

53. Rosenthal DI, Harris J, Forastiere AA, Weber RS, Ridge JA, Myers JN, Garden AS, Kuettel MR, Sidhu K, SCHULTZ CJ, Ang KK: Early Postoperative Paclitaxel Followed by Concurrent Paclitaxel-Cisplatin with Radiation Therapy for Patients with Resected, High-Risk Head and Neck Squamous Cell Carcinoma: Report of the Phase II Trial RTOG 0024. J Clin Oncol 27(28): 4727-4732, 2009.

54. Ahunbay EE, Peng C, Godley A, SCHULTZ C, Li XA. An on-line replanning method for head and neck adaptive radiotherapy. Med Phys. 2009 Oct;36(10):4776-90.

55. Parker SM. Olteanu H. Vantuinen P. Lawton CA. SCHULTZ CJ. Christians KK. Fenske TS. Follicular lymphoma transformation to dual translocated Burkitt-like lymphoma: improved disease control associated with radiation therapy. Int J Hematol 90(5):616-22, 2009.

56. Vogelbaum MA, Berkey B, Peereboom D, Macdonald D, Giannini C, Suh JH, Jenkins R, Herman J, Brown P, Blumenthal DT, Biggs C, SCHULTZ C, Mehta M. Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131. Neuro Oncol. 2009 Apr;11(2):167-75. PMCID: PMC2718988

57. Rosenthal DI, Harris J, Forastiere AA, Weber RS, Ridge JA, Myers JN, Garden AS, Kuettel MR, Sidhu K, SCHULTZ CJ, Trotti A, Ang KK. Early postoperative paclitaxel followed by concurrent paclitaxel and cisplatin with radiation therapy for patients with resected high-risk head and neck squamous cell carcinoma: report of the phase II trial RTOG 0024. J Clin Oncol. 2009 Oct 01;27(28):4727-32. PMCID: PMC2754914

58. Shuff JH, Siker ML, Daly MD, SCHULTZ CJ. Role of radiation therapy in cutaneous melanoma. Clin Plast Surg. 2010 Jan;37(1):147-60.

59. SCHULTZ, CJ, Bovi, J: Current management of primary central nervous system lymphoma. Int J Radiat Oncol Biol Phys 76(3):666-678, 2010.

60. Choucair A, Moughan J, SCHULTZ C, Schulsinger A, Mehta M, Curran W. Prognostic value of H-MLH1 after adjusting for RPA class in GBM patients. Front Biosci (Elite Ed). 2011 Jun 01;3:1182-91.

61. Paulson ES, Bradley JA, Wang D, Ahunbay EE, SCHULTZ C, Li XA. Internal margin assessment using cine MRI analysis of deglutition in head and neck cancer radiotherapy. Med Phys. 2011 Apr;38(4):1740-7.

62. Zundel MT, Michel M, SCHULTZ C, et al: Comparison of physical examination and fluorodeoxyglucose position emission tomography/computed tomography 4-6 months after radiotherapy to assess residual head and neck cancer. Int J Radiat Oncol Biol Phys 81(5) 825-832, 2011.

63. McHaffie DR, Chabot P, Dagnault A, Suh JH, Fortin MA, Chang E, Timmerman R, Souhami L, Grecula J, Nabid A, SCHULTZ C, Werner-Wasik M, Gaspar LE, Brachman D, Mody T, Mehta MP. Safety and feasibility of motexafin gadolinium administration with whole brain radiation therapy and stereotactic radiosurgery boost in the treatment of ≤ 6 brain metastases: a multi-institutional phase II trial. J Neurooncol. 2011 Nov;105(2):301-8.

64. Bradley JA, Paulson ES, Ahunbay E, SCHULTZ C, Li XA, Wang D. Dynamic MRI analysis of tumor and organ motion during rest and deglutition and margin assessment for radiotherapy of head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2011 Dec 01;81(5):e803-12.

65. Siker M, Firat S, Mueller W, Krouwer H, SCHULTZ C: Semi-continuous low-dose-rate teletherapy for the treatment of recurrent glial brain tumors: Final report of a phase I/II study. Int J Radiat Oncol Biol Phys 82(2) 765-772, Feb 2012.

66. Kharofa J, Choong N, Wang D, Firat S, SCHULTZ C, Sadasiwan C, Wong S. Continuous-course reirradiation with concurrent carboplatin and paclitaxel for locally recurrent, nonmetastatic squamous cell carcinoma of the head-and-neck. Int J Radiat Oncol Biol Phys. 2012 Jun 01;83(2):690-5.

67. Bedi M, Firat S, Semenenko VA, SCHULTZ C, Tripp P, Byhardt R, Wang D. Elective lymph node irradiation with intensity-modulated radiotherapy: is conventional dose fractionation necessary? Int J Radiat Oncol Biol Phys. 2012 May 01;83(1):e87-92.

68. Hartford AC, Galvin JM, Beyer DC, Eichler TJ, Ibbott GS, Kavanagh B, SCHULTZ CJ, Rosenthal SA, American College of Radiology, American Society for Radiation Oncology. American College of Radiology (ACR) and American Society for Radiation Oncology (ASTRO) Practice Guideline for Intensity-modulated Radiation Therapy (IMRT). Am J Clin Oncol. 2012 Dec;35(6):612-7.

69. Cooper JS, Zhang Q, Pajak TF, Forastiere AA, Jacobs J, Saxman SB, Kish JA, Kim HE, Cmelak AJ, Rotman M, Lustig R, Ensley JF, Thorstad W, SCHULTZ CJ, Yom SS, Ang KK. Long-term follow-up of the RTOG 9501/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 2012 Dec 01;84(5):1198-205. PMCID: PMC3465463

70. Chakravarti A, Wang M, Robins HI, Lautenschlaeger T, Curran WJ, Brachman DG, SCHULTZ CJ, Choucair A, Dolled-Filhart M, Christiansen J, Gustavson M, Molinaro A, Mischel P, Dicker AP, Bredel M, Mehta M. RTOG 0211: a phase 1/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients. Int J Radiat Oncol Biol Phys. 2013 Apr 01;85(5):1206-11. PMCID: PMC4199329

71. Seung SK, Larson DA, Galvin JM, Mehta MP, Potters L, SCHULTZ CJ, Yajnik SV, Hartford AC, Rosenthal SA. American College of Radiology (ACR) and American Society for Radiation Oncology (ASTRO) Practice Guideline for the Performance of Stereotactic Radiosurgery (SRS). Am J Clin Oncol. 2013 Jun;36(3):310-5. PMCID: PMC4285440

72. Sabsevitz DS, Bovi JA, Leo PD, Laviolette PS, Rand SD, Mueller WM, SCHULTZ CJ. The role of pre-treatment white matter abnormalities in developing white matter changes following whole brain radiation: a volumetric study. J Neurooncol. 2013 Sep;114(3):291-7.

73. Gilbert MR, Wang M, Aldape KD, Stupp R, Hegi ME, Jaeckle KA, Armstrong TS, Wefel JS, Won M, Blumenthal DT, Mahajan A, SCHULTZ CJ, Erridge S, Baumert B, Hopkins KI, Tzuk-Shina T, Brown PD, Chakravarti A, Curran WJ Jr, Mehta MP. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol. 2013 Nov 10;31(32):4085-91. PMCID: PMC3816958

74. Krauze AV, Won M, Graves C, Corn BW, Muanza TM, Howard SP, Mahadevan A, SCHULTZ CJ, Haas ML, Mehta MP, Camphausen KA. Predictive value of tumor recurrence using urinary vascular endothelial factor levels in patients receiving radiation therapy for Glioblastoma Multiforme (GBM). Biomark Res. 2013 Oct 31;1(1):29. PMCID: PMC4177620

75. Yang C, Liu F, Ahunbay E, Chang YW, Lawton C, SCHULTZ C, Wang D, Erickson B, Li XA: Combined online and offline adaptive radiation therapy: A dosimetric feasibility study. Pract Radiat Oncol (PRO) 4, e75-e83, Jan/Feb 2014.

76. Elson A, Bovi J, Kaur K, Maas D, Sinson G, SCHULTZ C. Effect of treatment modality on the hypothalamic-pituitary function of patients treated with radiation therapy for pituitary adenomas: hypothalamic dose and endocrine outcomes. Front Oncol. 2014;4:73. PMCID: PMC3988389

77. Elson A, Paulson E, Bovi J, Siker M, SCHULTZ C, Laviolette PS. Evaluation of pre-radiotherapy apparent diffusion coefficient (ADC): patterns of recurrence and survival outcomes analysis in patients treated for glioblastoma multiforme. J Neurooncol. 2015 May;123(1):179-88.

78. Feng M, Yang C, Chen X, Xu S, Moraru I, Lang J, SCHULTZ C, Li XA. Computed tomography number changes observed during computed tomography-guided radiation therapy for head and neck cancer. Int J Radiat Oncol Biol Phys. 2015 Apr 01;91(5):1041-7.

79. Yang C, Liu F, Ahunbay E, Chang YW, Lawton C, SCHULTZ C, Wang D, Firat S, Erickson B, Li XA. Combined online and offline adaptive radiation therapy: a dosimetric feasibility study. Pract Radiat Oncol. 2014 Jan-Feb;4(1):e75-83.

80. Elson A, Walker A, Bovi JA, SCHULTZ C. Use of Helical TomoTherapy for the Focal Hypofractionated Treatment of Limited Brain Metastases in the Initial and Recurrent Setting. Front Oncol. 2015;5:27. PMCID: PMC4321406

81. Elson A, Bovi J, Siker M, SCHULTZ C, Paulson E. Evaluation of absolute and normalized apparent diffusion coefficient (ADC) values within the post-operative T2/FLAIR volume as adverse prognostic indicators in glioblastoma. J Neurooncol. 2015 May;122(3):549-58.

82. Paulson ES, Erickson B, SCHULTZ C, Allen Li X. Comprehensive MRI simulation methodology using a dedicated MRI scanner in radiation oncology for external beam radiation treatment planning. Med Phys. 2015 Jan;42(1):28-39.

83. Kainz K, Firat S, Wilson JF, SCHULTZ C, Siker M, Wang A, Olson D, Li XA. Comparing the quality of passively-scattered proton and photon tomotherapy plans for brain and head and neck disease sites. Phys Med Biol. 2015 Mar 21;60(6):2167-77.

84. Buckner JC, Shaw EG, Pugh SL, Chakravarti A, Gilbert MR, Barger GR, Coons S, Ricci P, Bullard D, Brown PD, Stelzer K, Brachman D, Suh JH, SCHULTZ CJ, Bahary JP, Fisher BJ, Kim H, Murtha AD, Bell EH, Won M, Mehta MP, Curran WJ Jr. Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma. N Engl J Med. 2016 Apr 07;374(14):1344-55. PMCID: PMC5170873

85. Glass J, Won M, SCHULTZ CJ, Brat D, Bartlett NL, Suh JH, Werner-Wasik M, Fisher BJ, Liepman MK, Augspurger M, Bokstein F, Bovi JA, Solhjem MC, Mehta MP. Phase I and II Study of Induction Chemotherapy With Methotrexate, Rituximab, and Temozolomide, Followed By Whole-Brain Radiotherapy and Postirradiation Temozolomide for Primary CNS Lymphoma: NRG Oncology RTOG 0227. J Clin Oncol. 2016 May 10;34(14):1620-5. PMCID: PMC4872318

86. Nguyen HS, Milbach N, Hurrell SL, Cochran E, Connelly J, Bovi JA, SCHULTZ CJ, Mueller WM, Rand SD, Schmainda KM, LaViolette PS. Progressing Bevacizumab-Induced Diffusion Restriction Is Associated with Coagulative Necrosis Surrounded by Viable Tumor and Decreased Overall Survival in Patients with Recurrent Glioblastoma. AJNR Am J Neuroradiol. 2016 Dec;37(12):2201-2208. PMCID: PMC5161572

87. Chen X, Prior P, Chen GP, Schultz CJ, Li XA. Technical Note: Dose effects of 1.5 T transverse magnetic field on tissue interfaces in MRI-guided radiotherapy. Med Phys. 2016 Aug;43(8):4797.

88. Nguyen HL, LaViolette P, SCHULTZ C, et al:PProgressing bevacizumab-induced diffusion restriction is associated with coagulative necrosis surrounded by viable tumor and decreased overall survival in recurrent glioblastoma patients. American Journal of Neuro-Oncology 2016, 37,2001-2008

89. Divi V, Harris J, Harari PM, Cooper JS, McHugh J, Bell D, Sturgis EM, Cmelak AJ, Suntharalingam M, Raben D, Kim H, Spencer SA, Laramore GE, Trotti A, Foote RL, Schultz C, Thorstad WL, Zhang Q, Le QT, Holsinger FC. Establishing quality indicators for neck dissection correlating the number of lymph nodes with oncoloigic outcomes, NRG Oncology/RTOG 9501 and 0234. Cancer Vol 122, #22. July 2016

90. Yao M, Zhang Q, Woods CR, Nguyen-Tan PF, Rosenthal DI, Garden AS, Thorstad WL, Anne PR, SCHULTZ CJ, Caudell JJ, Filion E, Ridge JA, Jones CU, Kim H, Yom SS, Raben D, Bonner JA, Machtay M, Harris J, Le QT. Intensity Modulated Radiation Therapy Versus 3-Dimensional Conformal Radiation Therapy in Head and Neck Squamous Cell Carcinoma: A Pooled Analysis of NRG Oncology/RTOG 0129 and 0522. Int J Radiat Oncol Biol Phys. 2016 Oct 1;96(2S):S116-S117.

91. Dayal A, Siker ML, Firat S, Bovi JA, SCHULTZ CJ, Mueller WM, Connelly JM, Rand SD. Clinical Significance of Updated MRI Simulation Versus Immediate Postoperative MRI for Radiation Treatment Planning in Patients With Glioblastoma: Changes in FLAIR Signal. Int J Radiat Oncol Biol Phys. 2016 Oct 1;96(2S):E103.

92. Siker ML, Firat S, Prah D, SCHULTZ CJ, Dayal A, Masterson C, Connelly JM, Mueller WM, Bovi JA. Pulsed Reduced Dose Rate Reirradiation (PRDR) Using Modulated Arc (mARC) Intensity Modulated Radiation Therapy for Recurrent Gliomas: Initial Clinical Outcomes of a Novel Technique. Int J Radiat Oncol Biol Phys. 2016 Oct 1;96(2S):E125-E126.

93. Bell EH, McElroy JP, Fleming J, Timmers C, Chakraborty AR, Salavaggione AL, Chang SM, Shaw EG, Aldape K, Brachman D, SCHULTZ CJ, Shih HA, Curtis M, Hunter GK, Murtha AD, Zhang P, Won M, Mehta MP, Chakravarti A. A Mutation and Prognostic Biomarker Study in Grade II and III Gliomas Utilizing a Combined Cohort of NRG Oncology/RTOG 9802 and 9813. Int J Radiat Oncol Biol Phys. 2016 Oct 1;96(2S):S91.

94. Kerkmeijer LG, Fuller CD, Verkooijen HM, Verheij M, Choudhury A, Harrington KJ, SCHULTZ C, Sahgal A, Frank SJ, Goldwein J, Brown KJ, Minsky BD, van Vulpen M, MR-Linac Consortium Clinical Steering Committee. The MRI-Linear Accelerator Consortium: Evidence-Based Clinical Introduction of an Innovation in Radiation Oncology Connecting Researchers, Methodology, Data Collection, Quality Assurance, and Technical Development. Front Oncol. 2016;6:215. PMCID: PMC5061756

95. Chang S, Zhang P, Cairncross JG, Gilbert MR, Bahary JP, Dolinskas CA, Chakravarti A, Aldape KD, Bell EH, Schiff D, Jaeckle K, Brown PD, Barger GR, Werner-Wasik M, Shih H, Brachman D, Penas-Prado M, Robins HI, Belanger K, SCHULTZ C, Hunter G, Mehta M. Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813. Neuro Oncol. 2017 02 01;19(2):252-258. PMCID: PMC5463834

96. Verkooijen HM, Kerkmeijer LGW, Fuller CD, Huddart R, Faivre-Finn C, Verheij M, Mook S, Sahgal A, Hall E, SCHULTZ C. R-IDEAL: A Framework for Systematic Clinical Evaluation of Technical Innovations in Radiation Oncology. Front Oncol. 2017;7:59. PMCID: PMC5378068

97. Bell E, Schultz CJ, et al: MGMT promoter methylation status predicts survival outcomes in NRG Oncology/RTOG 0424: A phase II trial of temozolomide chemoradiotherapy for high risk low grade gliomas (Submitted to JAMA Oncology 5/17)

98. Hall WA, Bergom C, Thompson RF, Baschnagel AM, Vijayakumar S, Willers H, Li XA, Schultz CJ, Wilson GD, West CML, Capala J, Coleman CN, Torres-Roca JF, Weidhaas J, Feng FY. Precision Oncology and Genomically Guided Radiation Therapy: A Report From the American Society for Radiation Oncology/American Association of Physicists in Medicine/National Cancer Institute Precision Medicine Conference. Int J Radiat Oncol Biol Phys. 2018 Jun 01;101(2):274-284.

99. Ali AN, Zhang P, Yung WKA, Chen Y, Movsas B, Urtasun RC, Jones CU, Choi KN, Michalski JM, Fischbach AJ, Markoe AM, Schultz CJ, Penas-Prado M, Garg MK, Hartford AC, Kim HE, Won M, Curran WJ Jr. NRG oncology RTOG 9006: a phase III randomized trial of hyperfractionated radiotherapy (RT) and BCNU versus standard RT and BCNU for malignant glioma patients. J Neurooncol. 2018 Mar;137(1):39-47. PMCID: PMC6020014

100. Lieberman FS, Wang M, Robins HI, Tsien CI, Curran WJ, Werner-Wasik M, Smith RP, SCHULTZ CS, Hartford AC, Zhang P, Mehta MP. Phase 2 Study of Radiation Therapy Plus Low Dose Temozolomide Followed by Temozolomide and Irinotecan for Glioblastoma: NRG Oncology RTOG Trial 0420. Int J Rad Onc Biol Phys, 2019 Mar 15;103(4):878-886. doi: 10.1016/j.ijrobp.2018.11.008. Epub 2018 Nov 27.

101. Gilbride L, Siker M, Bovi J, Gore E, Schultz C, Hall WA. Current Predictive Indices and Nomograms To Enable Personalization of Radiation Therapy for Patients With Secondary Malignant Neoplasms of the Central Nervous System: A Review. Neurosurgery. 2018 May 01;82(5):595-603.

102. Gilbride L, Siker M, Bovi J, Gore E, Schultz C, Hall WA. Current Predictive Indices and Nomograms To Enable Personalization of Radiation Therapy for Patients With Secondary Malignant Neoplasms of the Central Nervous System: A Review. Neurosurgery. 2018 May 01;82(5):595-603.

103. Wu H, Chen X, Yang X, Tao Y, Xia Y, Deng X, Zheng C, Robbins J, Schultz C, Li XA. Early Prediction of Acute Xerostomia During Radiation Therapy for Head and Neck Cancer Based on Texture Analysis of Daily CT. Int J Radiat Oncol Biol Phys. 2018 Nov 15;102(4):1308-1318.

104. Bell EH, Zhang P, Fisher BJ, Macdonald DR, McElroy JP, Lesser GJ, Fleming J, Chakraborty AR, Liu Z, Becker AP, Fabian D, Aldape KD, Ashby LS, Werner-Wasik M, Walker EM, Bahary JP, Kwok Y, Yu HM, Laack NN, Schultz CJ, Gray HJ, Robins HI, Mehta MP, Chakravarti A. Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide: An Analysis From the NRG Oncology/RTOG 0424 Trial. JAMA Oncol. 2018 Oct 01;4(10):1405-1409. PMCID: PMC6117103

105. Bovi JA, Schultz CJ, Mehta MP, Corn BW. Consolidative Whole-Brain Radiation Therapy Versus Autologous Stem Cell Transplant for Primary Central Nervous System Lymphoma: A Large Dose of Perspective and Perhaps a Lower Dose of Radiation Are in Order. Int J Radiat Oncol Biol Phys. 2018 Sep 01;102(1):59-60.

106. Lorenz J, Rein L, Mostafaei F, Noid G, Lawton C, Bedi M, Li A, Paulson E, Schultz C. Weekly MRI from a 1.5 TMR-Linac Reveals Intra-Treatment Signal Variance in Regional Organs at Risk: An Exploratory Analysis for Potential Novel Metrics of Normal Tissue Response. Submitted 9/2018

107. Lieberman FS, Wang M, Robins HI, Tsien CI, Curran WJ Jr, Werner-Wasik M, Smith RP, Schultz C, Hartford AC, Zhang P, Mehta MP. Phase 2 Study of Radiation Therapy Plus Low-Dose Temozolomide Followed by Temozolomide and Irinotecan for Glioblastoma: NRG Oncology RTOG Trial 0420. Int J Radiat Oncol Biol Phys. 2019 Mar 15;103(4):878-886. PMCID: PMC7034757

108. Zenga J, Graboyes E, Janz T, Drake V, Rettig E, Desai S, Nickel C, Shabani S, Padhya T, Scarpinato M, Stadler M, Massey B, Campbell B, Shukla M, Awan M, Schultz CJ, Wong S, Jackson RS, Pipkorn P. Salvage of Recurrence after Surgery and Adjuvant Therapy: A Multi-institutional Study. Otolaryngol Head Neck Surg. 2019 Jul;161(1):74-81.

109. Zenga J, Stadler M, Massey B, Campbell B, Shukla M, Awan M, Schultz CJ, Wong S, Jackson RS, Pipkorn P. Lymph node yield from neck dissection in HPV-associated oropharyngeal cancer. Laryngoscope. 2020 Mar;130(3):666-671.

110. Lorenz JW, Schott D, Rein L, Mostafaei F, Noid G, Lawton C, Bedi M, Li XA, Schultz CJ, Paulson E, Hall WA. Serial T2-Weighted Magnetic Resonance Images Acquired on a 1.5 Tesla Magnetic Resonance Linear Accelerator Reveal Radiomic Feature Variation in Organs at Risk: An Exploratory Analysis of Novel Metrics of Tissue Response in Prostate Cancer. Cureus. 2019 Apr 20;11(4):e4510. PMCID: PMC6590865

111. Schultz C, et al. Lymph Node Yield, Depth of Invasion, and Survival in Node-Negative Oral Cavity Cancer. Accepted for publication in Oral Oncology, October 2019.

112. Hall WA, Paulson ES, van der Heide UA, Fuller CD, Raaymakers BW, Lagendijk JJW, Li XA, Jaffray DA, Dawson LA, Erickson B, Verheij M, Harrington KJ, Sahgal A, Lee P, Parikh PJ, Bassetti MF, Robinson CG, Minsky BD, Choudhury A, Tersteeg RJHA, Schultz CJ, MR Linac Atlantic Consortium and the ViewRay C2T2 Research Consortium. The transformation of radiation oncology using real-time magnetic resonance guidance: A review. Eur J Cancer. 2019 Nov;122:42-52. PMCID: PMC8447225

113. Zenga J, Divi V, Stadler M, Massey B, Campbell B, Shukla M, Awan M, Schultz CJ, Shreenivas A, Wong S, Jackson RS, Pipkorn P. Lymph node yield, depth of invasion, and survival in node-negative oral cavity cancer. Oral Oncol. 2019 Nov;98:125-131.

114. Schultz CJ. Reassessing the Role of Radiation Therapy for the Treatment of Lymphoma: Historical Perspective and Opportunities in the Era of Image-Guided and Adaptive Radiation Therapy. J Oncol Pract. 2019 Apr;15(4):175-176.

115. Tai A, Schultz C, li X. SU‐E‐CAMPUS‐J‐05: Extracting Patient‐Specific Radiobiological Parameters From Tumor Regression for Biologically‐Based Adaptive Radiation Therapy of Head and Neck Cancer Medical Physics. June 2013;40(6):379.

116. Kainz K, Wang W, Firat S, Wilson J, Schultz C, li X. SU‐E‐CAMPUS‐T‐04: Plan Quality of Proton Vs. Photon IMRT for Whole Ventricle Irradiation Medical Physics. June 2013;40(6):380.

117. Chen G, Hu B, Qi S, Schultz C, Wang D, Li X. SU‐FF‐T‐591: Improvement of IMRT Plan Quality with Non‐Isocentric Beam Arrangement for Head and Neck Cancers Medical Physics. June 2009;36(6):2660.

118. Abrey LE, Ben-Porat L, Panageas KS, Yahalom J, Curran W, Schultz C, Leibel S, Nelson D, Mehta M, DeAngelis LM. In reply [9] Journal of Clinical Oncology. 20 September 2007;25(27):4324-4325.

119. Kainz K, Wilson JF, Schultz C, Jursinic P, li XA. TU‐FF‐A2‐03: Image‐Guided Helical Tomotherapy to Treat Advanced Cancers of the Scalp: Prospects for Dose Conformity and Clinical Outcome Medical Physics. June 2007;34(6):2576.

120. li X, Stewart R, Semenenko V, qi S, Chen G, Ahunbay E, Schultz C. SU‐FF‐T‐54: A Three‐Phase Strategy for a Partial Implementation of Biologically Guided Radiation Therapy Medical Physics. June 2007;34(6):2413.

121. li X, qi X, Mueller K, Jursinic P, Erickson B, Wang D, Schultz C, Firat S, Wilson J. SU‐FF‐J‐122: Systematic Study of Inter‐Fractional Variations for Anatomic Sites From Head to Feet Medical Physics. June 2006;33(6):2048.

122. Li X, Ahunbay E, Qi X, Schultz C. SU‐FF‐T‐382: Planning Non‐Uniform Dose Distributions for Brain Tumor Medical Physics. June 2005;32(6):2038-2039.

123. Ahunbay E, Schmainda K, Lund R, Prost R, Ulmer J, Alaly J, Deasy J, Schultz C, li X. SU‐FF‐J‐105: Tools for Voxel‐By‐Voxel Correlation of Radiotherapy Dose and MR Signals From Multiple Physiological/functional MRI Modalities Medical Physics. June 2005;32(6):1944.

124. Prados MD, Seiferheld W, Sandler HM, Buckner JC, Phillips T, Schultz C, Urtasun R, Davis R, Gutin P, Cascino TL, Greenberg HS, Curran WJ Jr. Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: final report of RTOG 9404. Int J Radiat Oncol Biol Phys. 2004 Mar 15;58(4):1147-52.

125. Mehta MP, Rodrigus P, Terhaard CH, Rao A, Suh J, Roa W, Souhami L, Bezjak A, Leibenhaut M, Komaki R, Schultz C, Timmerman R, Curran W, Smith J, Phan SC, Miller RA, Renschler MF. Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J Clin Oncol. 2003 Jul 01;21(13):2529-36.

126. Spencer SA, Harris J, Wheeler RH, Machtay M, Schultz C, Spanos W, Rotman M, Meredith R. RTOG 96-10: reirradiation with concurrent hydroxyurea and 5-fluorouracil in patients with squamous cell cancer of the head and neck. Int J Radiat Oncol Biol Phys. 2001 Dec 01;51(5):1299-304.

127. Prados MD, Scott C, Sandler H, Buckner JC, Phillips T, Schultz C, Urtasun R, Davis R, Gutin P, Cascino TL, Greenberg HS, Curran WJ Jr. A phase 3 randomized study of radiotherapy plus procarbazine, CCNU, and vincristine (PCV) with or without BUdR for the treatment of anaplastic astrocytoma: a preliminary report of RTOG 9404. Int J Radiat Oncol Biol Phys. 1999 Dec 01;45(5):1109-15.

128. Robins HI, Eickhoff J, Gilbert MR, Armstrong TS, Shi W, De Groot JF, Schultz CJ, Hunter GK, Valeinis E, Roach M, Youssef EF, Souhami L, Howard SP, Lieberman FS, Herman JG, Zhang P, Mehta MP. The association between BMI and BSA-temozolomideinduced myelosuppression toxicities: A correlative analysis of NRG oncology RTOG 0525 Neuro-Oncology Practice. 1 December 2019;6(6):473-478.

129. North L, Stadler M, Massey B, Campbell B, Shukla M, Awan M, Schultz CJ, Shreenivas A, Wong S, Graboyes E, Pipkorn P, Zenga J. Intermediate-grade carcinoma of the parotid and the impact of adjuvant radiation. Am J Otolaryngol. 2019;40(6):102282.

130. Paulson ES, Ahunbay E, Chen X, Mickevicius NJ, Chen GP, Schultz C, Erickson B, Straza M, Hall WA, Li XA. 4D-MRI driven MR-guided online adaptive radiotherapy for abdominal stereotactic body radiation therapy on a high field MR-Linac: Implementation and initial clinical experience Clinical and Translational Radiation Oncology. July 2020;23:72-79.

131. Kish J, Zhang E, Langer C, Nguyen-Tan PF, Rosenthal D, Weber R, List MA, Wong S, Garden A, Hu KS, Trotti A, Bonner JA, Jones C, Yom S, Thorstad W, SCHULTZ C, Ridge J, Shenouda G, Le QT. The impact of age on outcome in prospective, Phase III NRG Oncology/RTOG trials of radiotherapy (XRT) +/- systemic therapy in locally advanced head and neck cancer. Submitted for publication in Journal of Geriatric Oncology, Submission no: JGO_2020_267

132. Paulson ES, Ahunbay E, Chen X, Mickevicius NJ, Chen GP, Schultz C, Erickson B, Straza M, Hall WA, Li XA. 4D-MRI driven MR-guided online adaptive radiotherapy for abdominal stereotactic body radiation therapy on a high field MR-Linac: Implementation and initial clinical experience. Clin Transl Radiat Oncol. 2020 Jul;23:72-79. PMCID: PMC7256110

133. Bovi JA, Prah MA, Retzlaff AA, Schmainda KM, Connelly JM, Rand SD, Marszalkowski CS, Mueller WM, Siker ML, Schultz CJ. Pulsed Reduced Dose Rate Radiotherapy in Conjunction With Bevacizumab or Bevacizumab Alone in Recurrent High-grade Glioma: Survival Outcomes. Int J Radiat Oncol Biol Phys. 2020 Nov 15;108(4):979-986. PMCID: PMC8655709

134. Hall W, Chen X, Mickevicius N, Erickson B, SCHULTZ C, Awan M, Paulson ES, Li XA, Ahunbay E, Straza MW. Initial Clinical Experience of Stereotactic Body Radiation Therapy (SBRT) For Liver Metastases, Primary Liver Malignancy, and Pancreatic Cancer with 4D-MRI based Online Adaptation and Real-Time MRI Monitoring using a 1.5 Tesla MR-Linac. Accepted for publication in PLOS ONE.

135. Noid G, Zhu J, Tai A, Mistry N, Schott D, Prah D, Paulson E, SCHULTZ C, Li XA. Improving structure delineation for radiation therapy planning using dual-energy CT. Accepted for publication in Frontiers in Oncology, section Radiation Oncology.

136. Hall WA, Straza MW, Chen X, Mickevicius N, Erickson B, Schultz C, Awan M, Ahunbay E, Li XA, Paulson ES. Initial clinical experience of Stereotactic Body Radiation Therapy (SBRT) for liver metastases, primary liver malignancy, and pancreatic cancer with 4D-MRI based online adaptation and real-time MRI monitoring using a 1.5 Tesla MR-Linac. PLoS One. 2020;15(8):e0236570. PMCID: PMC7413561

137. de Mol van Otterloo SR, Christodouleas JP, Blezer ELA, Akhiat H, Brown K, Choudhury A, Eggert D, Erickson BA, Faivre-Finn C, Fuller CD, Goldwein J, Hafeez S, Hall E, Harrington KJ, van der Heide UA, Huddart RA, Intven MPW, Kirby AM, Lalondrelle S, McCann C, Minsky BD, Mook S, Nowee ME, Oelfke U, Orrling K, Sahgal A, Sarmiento JG, Schultz CJ, Tersteeg RJHA, Tijssen RHN, Tree AC, van Triest B, Hall WA, Verkooijen HM. The MOMENTUM Study: An International Registry for the Evidence-Based Introduction of MR-Guided Adaptive Therapy Frontiers in Oncology. 7 September 2020;10.

138. Noid G, Zhu J, Tai A, Mistry N, Schott D, Prah D, Paulson E, Schultz C, Li XA. Improving Structure Delineation for Radiation Therapy Planning Using Dual-Energy CT Frontiers in Oncology. 28 August 2020;10.

139. Bell EH, Zhang P, Shaw EG, Buckner JC, Barger GR, Bullard DE, Mehta MP, Gilbert MR, Brown PD, Stelzer KJ, McElroy JP, Fleming JL, Timmers CD, Becker AP, Salavaggione AL, Liu Z, Aldape K, Brachman DG, Gertler SZ, Murtha AD, Schultz CJ, Johnson D, Laack NN, Hunter GK, Crocker IR, Won M, Chakravarti A. Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma. J Clin Oncol. 2020 Oct 10;38(29):3407-3417. PMCID: PMC7527157

140. Noid G, Zhu J, Tai A, Mistry N, Schott D, Prah D, Paulson E, Schultz C, Li XA. Improving Structure Delineation for Radiation Therapy Planning Using Dual-Energy CT. Front Oncol. 2020;10:1694. PMCID: PMC7484725

141. de Mol van Otterloo SR, Christodouleas JP, Blezer ELA, Akhiat H, Brown K, Choudhury A, Eggert D, Erickson BA, Faivre-Finn C, Fuller CD, Goldwein J, Hafeez S, Hall E, Harrington KJ, van der Heide UA, Huddart RA, Intven MPW, Kirby AM, Lalondrelle S, McCann C, Minsky BD, Mook S, Nowee ME, Oelfke U, Orrling K, Sahgal A, Sarmiento JG, Schultz CJ, Tersteeg RJHA, Tijssen RHN, Tree AC, van Triest B, Hall WA, Verkooijen HM. The MOMENTUM Study: An International Registry for the Evidence-Based Introduction of MR-Guided Adaptive Therapy. Front Oncol. 2020;10:1328. PMCID: PMC7505056

142. Fleming JL, Pugh S, Bell EH, Chang SM, McElroy J, Becker A, Timmers CD, Shih HA, Ashby L, Hunter GK, Bahary JP, Schultz CJ, Kavanagh BD, Yung WA, Robins I, Werner-Wasik M, Chakravarti A. Prognostic Significance of IDH1/2 Mutation and MGMT Promoter Methylation Status in RTOG 9813. Int J Radiat Oncol Biol Phys. 2020 Dec 01;108(5):1399.

143. Bovi JA, Schultz CJ. In Reply to Peñagarícano. Int J Radiat Oncol Biol Phys. 2021 Feb 01;109(2):641.

144. Bero E, SCHULTZ C, et al. Characterization of Underrepresented Populations in Modern Era Clinical Trials Involving Radiation Therapy. Accepted for publication in Pract Rad Onc, March 2021.

145. Kish JA, Zhang Q, Langer CJ, Nguyen-Tân PF, Rosenthal DI, Weber RS, List MA, Wong SJ, Garden AS, Hu K, Trotti AM, Bonner JA, Jones CU, Yom SS, Thorstad W, Schultz CJ, Ridge JA, Shenouda G, Harris J, Le QT. The impact of age on outcome in phase III NRG Oncology/RTOG trials of radiotherapy (XRT) +/- systemic therapy in locally advanced head and neck cancer. J Geriatr Oncol. 2021 Jul;12(6):937-944. PMCID: PMC8829803

146. Robins HI, Eickhoff J, Gilbert MR, Armstrong TS, Shi W, De Groot JF, Schultz CJ, Hunter GK, Valeinis E, Roach M 3rd, Youssef EF, Souhami L, Howard SP, Lieberman FS, Herman JG, Zhang P, Mehta MP. The association between BMI and BSA-temozolomide-induced myelosuppression toxicities: a correlative analysis of NRG oncology RTOG 0525. Neurooncol Pract. 2019 Dec;6(6):473-478. PMCID: PMC6899045

147. Vassilakopoulou M, Minhee W, Curran W, Souhami L, Prados M, Langer C, Rimm D, Hanna J, Neumeister V, Melian E, Diaz A, Atkins J, Komarnicky L, SCHULTZ C, Howard S, Zhang P, Dicker A, Knisely J. BRCA1 Protein Expression Predicts Survival in Glioblastoma Patients from an NRG Oncology RTOG Cohort. Oncology 2021 May 6;1-9.

148. Vassilakopoulou M, Won M, Curran WJ, Souhami L, Prados MD, Langer CJ, Rimm DL, Hanna JA, Neumeister VM, Melian E, Diaz AZ, Atkins JN, Komarnicky LT, Schultz CJ, Howard SP, Zhang P, Dicker AP, Knisely JPS. BRCA1 Protein Expression Predicts Survival in Glioblastoma Patients from an NRG Oncology RTOG Cohort. Oncology. 2021;99(9):580-588. PMCID: PMC8491475

149. Puccia R, Ramamurthi A, Grond SE, McCormick C, Ng A, Stadler M, Massey B, Campbell B, Shukla M, Awan M, Schultz C, Wong S, Shreenivas A, Zenga J. A closer look at 30 day hospital readmissions after head and neck cancer surgery American Journal of Otolaryngology - Head and Neck Medicine and Surgery. 1 September 2021;42(5).

150. de Mol van Otterloo SR, Christodouleas JP, Blezer ELA, Akhiat H, Brown K, Choudhury A, Eggert D, Erickson BA, Daamen LA, Faivre-Finn C, Fuller CD, Goldwein J, Hafeez S, Hall E, Harrington KJ, van der Heide UA, Huddart RA, Intven MPW, Kirby AM, Lalondrelle S, McCann C, Minsky BD, Mook S, Nowee ME, Oelfke U, Orrling K, Philippens MEP, Sahgal A, Schultz CJ, Tersteeg RJHA, Tijssen RHN, Tree AC, van Triest B, Tseng CL, Hall WA, Verkooijen HM, MR-Linac Consortium. Patterns of Care, Tolerability, and Safety of the First Cohort of Patients Treated on a Novel High-Field MR-Linac Within the MOMENTUM Study: Initial Results From a Prospective Multi-Institutional Registry. Int J Radiat Oncol Biol Phys. 2021 Nov 15;111(4):867-875. PMCID: PMC9764331

151. A. Dayal M.L. Siker S. Firat J.A. Bovi C.J. Schultz W.M. Mueller J.M. Connelly S.D. Rand. Clinical Significance of Updated MRI Simulation Versus Immediate Postoperative MRI for Radiation Treatment Planning in Patients With Glioblastoma: Changes in FLAIR Signal International Journal of Radiation Oncology, Biology, Physics. POSTER VIEWING ABSTRACT| VOLUME 96, ISSUE 2, SUPPLEMENT , E103, OCTOBER 01, 2016.

152. M.L. Siker S. Firat D. Prah C.J. Schultz A. Dayal C. Masterson J.M. Connelly W.M. Mueller J.A. Bovi . Pulsed Reduced Dose Rate Reirradiation (PRDR) Using Modulated Arc (mARC) Intensity Modulated Radiation Therapy for Recurrent Gliomas: Initial Clinical Outcomes of a Novel Technique International Journal of Radiation Oncology, Biology, Physics. POSTER VIEWING ABSTRACT| VOLUME 96, ISSUE 2, SUPPLEMENT , E125-E126, OCTOBER 01, 2016.

153. M. Yao Q. Zhang C.R. Woods P.F. Nguyen-Tan D.I. Rosenthal A.S. Garden W.L. Thorstad P.R. Anne C.J. Schultz J.J. Caudell E. Filion J.A. Ridge C.U. Jones H. Kim S.S. Yom D. Raben J.A. Bonner M. Machtay J. Harris Q.T. Le. Intensity Modulated Radiation Therapy Versus 3-Dimensional Conformal Radiation Therapy in Head and Neck Squamous Cell Carcinoma: A Pooled Analysis of NRG Oncology/RTOG 0129 and 0522 International Journal of Radiation Oncology, Biology, Physics. ORAL SCIENTIFIC SESSION| VOLUME 96, ISSUE 2, SUPPLEMENT , S116-S117, OCTOBER 01, 2016.

154. E.H. Bell J.P. McElroy J. Fleming C. Timmers A.R. Chakraborty A.L. Salavaggione S.M. Chang E.G. Shaw K. Aldape D. Brachman C.J. Schultz H.A. Shih M. Curtis G.K. Hunter A.D. Murtha P. Zhang M. Won M.P. Mehta A. Chakravarti. A Mutation and Prognostic Biomarker Study in Grade II and III Gliomas Utilizing a Combined Cohort of NRG Oncology/RTOG 9802 and 9813 International Journal of Radiation Oncology, Biology, Physics. ORAL SCIENTIFIC SESSION| VOLUME 96, ISSUE 2, SUPPLEMENT , S91, OCTOBER 01, 2016.

155. Awan MJ, Gittleman H, Barnholtz-Sloan J, Machtay M, Nguyen-Tan PF, Rosenthal DI, Schultz C, Huth BJ, Thorstad WL, Frank SJ, Kim H, Foote RL, Lango MN, Shenouda G, Suntharalingam M, Harris J, Zhang Q, Le QT, Yao M, NRG Oncology Group. Risk groups of laryngeal cancer treated with chemoradiation according to nomogram scores - A pooled analysis of RTOG 0129 and 0522. Oral Oncol. 2021 May;116:105241. PMCID: PMC8144062

156. Hall WA, Paulson E, Li XA, Erickson B, Schultz C, Tree A, Awan M, Low DA, McDonald BA, Salzillo T, Glide-Hurst CK, Kishan AU, Fuller CD. Magnetic resonance linear accelerator technology and adaptive radiation therapy: An overview for clinicians. CA Cancer J Clin. 2022 Jan;72(1):34-56. PMCID: PMC8985054

157. Bero EH, Rein LE, Banerjee A, Straza MW, Lawton CAF, Schultz CJ, Erickson BA, Siker ML, Hall WA. Characterization of Underrepresented Populations in Modern Era Clinical Trials Involving Radiation Therapy. Pract Radiat Oncol. 2021;11(6):453-459.

158. Schottstaedt AM, Paulson ES, Rubenstein J, Chen X, Omari E, Li A, Gore EM, Schultz CJ, Hall WA. Development of a Comprehensive Cardiac MRI Atlas of Half Fourier-Acquired Single-Shot Turbo Spin-Echo (HASTE) and 3D Balanced Steady-State Free Precession (bSSFP) Sequences Prospectively Acquired From a 1.5T MR-Linac International journal of radiation oncology, biology, physics. 1 November 2021;111(3):e75-e76.

159. Raldow A, Siker ML, Bonner JA, Chen Y, Liu FF, Metz JM, Movsas B, Potters L, Schultz CJ, Sanders T, Wang X, Steinberg ML, Jagsi R. Assessment of Differences in Academic Rank and Salary by Gender and Race Among United States Academic Radiation Oncologists International journal of radiation oncology, biology, physics. 1 November 2021;111(3):e338-e339.

160. Conger R, Mora J, Straza MW Jr, Erickson BA, Lawton CAF, Schultz CJ, Currey AD, Bedi M, Saeed H, Tsai S, Siker ML, Hall WA. Evolution in the Presence and Evidence Category of Radiation Therapy Treatment Recommendations in National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Int J Radiat Oncol Biol Phys. 2021 Nov 01;111(3S):e105.

161. Cooper B, Bedi M, Bovi JA, Currey AD, Erickson BA, Gore EM, Hall WA, Lawton CAF, Schultz CJ, Siker ML, Saeed H. Enhancing Patient-Physician Experience in the Digital Era: A Review of Mobile Health Applications for Oncology Patients. Int J Radiat Oncol Biol Phys. 2021 Nov 01;111(3S):e105-e106.

162. Wittman D, Paulson ES, Eastwood D, Banerjee A, Banla LI, Schultz CJ, Awan MJ, Chen X, Omari E, Straza MW Jr, Li A, Erickson BA, Hall WA. Quantification and Dosimetric Impact of Normal Organ Motion During Adaptive Radiation Therapy Plan Verification Using a 1.5 Tesla Magnetic Resonance Equipped Linear Accelerator (MR LINAC). Int J Radiat Oncol Biol Phys. 2021 Nov 01;111(3S):S48-S49.

163. Quashie E, Tai A, Prior PW Jr, Awan MJ, Schultz CJ, Li A. A Practical Workflow to Calculate 3D BED Composite Plan Using Organ-Specific Radiobiological Parameters. Int J Radiat Oncol Biol Phys. 2021 Nov 01;111(3S):e242.

164. SCHULTZ, et al. Daily Changes in Diffusion Weighted Imaging Metrics During Stereotactic Body Radiation Therapy on 1.5T MR-Linac. Radiology. Submitted November 2021

165. García-Alvarez JA, Zhong H, Schultz CJ, Li XA, Kainz K. Incorporating uncertainty bounds in daily deformable dose accumulation for adaptive radiation therapy of head-and-neck cancer. Med Phys. 2023 Apr;50(4):2474-2487.

166. Zhong H, Garcia-Alvarez JA, Kainz K, Tai A, Ahunbay E, Erickson B, Schultz CJ, Li XA. Development of a multi-layer quality assurance program to evaluate the uncertainty of deformable dose accumulation in adaptive radiotherapy. Med Phys. 2023 Mar;50(3):1766-1778. PMCID: PMC10033340

167. Amidon RF, Santos-Pinheiro F, Straza M, Prah MA, Mueller WM, Krucoff MO, Connelly JM, Kleefisch CJ, Coss DJ, Cochran EJ, Bovi JA, Schultz CJ, Schmainda KM. Case report: Fractional brain tumor burden magnetic resonance mapping to assess response to pulsed low-dose-rate radiotherapy in newly-diagnosed glioblastoma. Front Oncol. 2022;12:1066191. PMCID: PMC9763264

168. SCHULTZ et al. Comprehensive Molecular Genomic Analysis in NRG Oncology/RTOG 9813: A Phase III Study of Radiation and Temozolomide Versus Radiation and BCNU/CCNU in Anaplastic Astrocytoma. Accepted in JAMA Oncology, February 2023.

169. Conger RL, Mora J, Straza MW, Erickson BA, Lawton CAF, Schultz CJ, Currey A, Bedi M, Siker ML, Hall WA. Evolution in the Presence and Evidence Category of Radiation Therapy Treatment Recommendations in the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Adv Radiat Oncol. 2023;8(4):101206. PMCID: PMC10157111

170. Raldow AC, Siker ML, Bonner JA, Chen Y, Liu FF, Metz JM, Movsas B, Potters L, Schultz CJ, Wilson E, Wang X, Romero T, Steinberg ML, Jagsi R. Assessment of Differences in Academic Rank and Compensation by Gender and Race/Ethnicity Among Academic Radiation Oncologists in the United States. Adv Radiat Oncol. 2023;8(5):101210. PMCID: PMC10160693

171. SCHULTZ, et al. Changes in Daily Apparent Diffusion Coefficient on Fully Quantitative Magnetic Resonance Imaging Correlate with Established Genomic Pathways of Radiation Sensitivity and Reveal Novel Biologic Associations. Submitted to Radiology, July 2023.

172. Amidon RF, Livingston K, Kleefisch CJ, Martens M, Straza M, Puckett L, Schultz CJ, Mueller WM, Connelly JM, Noid G, Morris K, Bovi JA. Cystic Brain Metastasis Outcomes After Gamma Knife Radiation Therapy Advances in Radiation Oncology. 2023.

173. Quashie EE, Li XA, Prior P, Awan M, Schultz C, Tai A. Obtaining organ-specific radiobiological parameters from clinical data for radiation therapy planning of head and neck cancers. Phys Med Biol. 2023 Dec 11;68(24).

174. Schottstaedt AM, Paulson ES, Rubenstein JC, Chen X, Omari EA, Li XA, Schultz CJ, Puckett LL, Robinson CG, Alongi F, Gore EM, Hall WA. Development of a comprehensive cardiac atlas on a 1.5 Tesla Magnetic Resonance Linear Accelerator Physics and Imaging in Radiation Oncology. October 2023;28.

175. Kelly JC, Wasserman GS, Bernard WD, Schultz C, Knapp J. Chloroquine poisoning in a child. Ann Emerg Med. 1990 Jan;19(1):47-50.

176. Jacobs JP, Murray KJ, Schultz CJ, Wilson JF, Goswitz MS, Stevens CW, Cox JD. Central lymphatic irradiation for stage III nodular malignant lymphoma: long-term results. J Clin Oncol. 1993 Feb;11(2):233-8.

177. Rock DB, Schultz CJ, Murray KJ, Wilson JF, Cox JD. Continuous split course irradiation for stage I and II Hodgkin's disease: 20 year experience at the Medical College of Wisconsin. Radiother Oncol. 1994 Mar;30(3):222-6.

178. Schultz CJ, Gaffney DK, Lindstrom MJ, Kinsella TJ. Iododeoxyuridine radiosensitization of human glioblastoma cells exposed to acute and chronic gamma irradiation: mechanistic implications and clinical relevance. Cancer J Sci Am. 1995;1(2):151-61.

179. Schultz CJ, Campbell BH, Freije JE, Brook BJ, McAuliffe TL. Risk factors which predict persistent cancer in the abnormal larynx following definitive irradiation. Eur J Cancer B Oral Oncol. 1995 Sep;31B(5):310-4.

180. Andryk J, Freije JE, Schultz CJ, Campbell BH, Komorowski RA. Lymphoepithelioma of the larynx. Am J Otolaryngol. 1996;17(1):61-3.

181. Rock DB, Murray KJ, Schultz CJ, Lauer SJ, Wilson JF. Stage I and II Hodgkin's disease in the pediatric population. Long-term follow-up of patients staged predominantly clinically. Am J Clin Oncol. 1996 Apr;19(2):174-8.

182. Schultz CJ. Demonstration of a brachytherapy boost dose-response relationship in glioblastoma multiforme: headed in the right direction. Int J Radiat Oncol Biol Phys. 1996 Apr 01;35(1):187-8.

183. Auchter RM, Lamond JP, Alexander E, Buatti JM, Chappell R, Friedman WA, Kinsella TJ, Levin AB, Noyes WR, Schultz CJ, Loeffler JS, Mehta MP. A multiinstitutional outcome and prognostic factor analysis of radiosurgery for resectable single brain metastasis. Int J Radiat Oncol Biol Phys. 1996 Apr 01;35(1):27-35.

184. Freije JE, Beatty TW, Campbell BH, Woodson BT, Schultz CJ, Toohill RJ. Carcinoma of the larynx in patients with gastroesophageal reflux. Am J Otolaryngol. 1996;17(6):386-90.

185. Campbell BH, Mark DH, Soneson EA, Freije JE, Schultz CJ. The role of dental prostheses in alveolar ridge squamous carcinomas. Arch Otolaryngol Head Neck Surg. 1997 Oct;123(10):1112-5.

186. Boyd TS, Harari PM, Tannehill SP, Voytovich MC, Hartig GK, Ford CN, Foote RL, Campbell BH, Schultz CJ. Planned postradiotherapy neck dissection in patients with advanced head and neck cancer. Head Neck. 1998 Mar;20(2):132-7.

187. Corn BW, Dolinskas C, Scott C, Donahue B, Schultz C, Nelson DF, Fisher B. Strong correlation between imaging response and survival among patients with primary central nervous system lymphoma: a secondary analysis of RTOG studies 83-15 and 88-06. Int J Radiat Oncol Biol Phys. 2000 May 01;47(2):299-303.

188. Michalski J, Purdy JA, Gaspar L, Souhami L, Ballow M, Bradley J, Chao CK, Crane C, Eisbruch A, Fallowil D, Forster K, Fowler J, Gillin MT, Graham ML, Harms WB, Huq MS, Kline RW, Mackie TR, Mukherji S, Podogorsak EB, Roach M, Ryu J, Sandler H, Schultz CJ, Schell M, Verhey LJ, Vicini F, Winter KA, Radiation Therapy Oncology Group. Radiation Therapy Oncology Group. Research Plan 2002-2006. Image-Guided Radiation Therapy Committee. Int J Radiat Oncol Biol Phys. 2001;51(3 Suppl 2):60-5.

189. Mehta MP, Shapiro WR, Glantz MJ, Patchell RA, Weitzner MA, Meyers CA, Schultz CJ, Roa WH, Leibenhaut M, Ford J, Curran W, Phan S, Smith JA, Miller RA, Renschler MF. Lead-in phase to randomized trial of motexafin gadolinium and whole-brain radiation for patients with brain metastases: centralized assessment of magnetic resonance imaging, neurocognitive, and neurologic end points. J Clin Oncol. 2002 Aug 15;20(16):3445-53.

190. DeAngelis LM, Seiferheld W, Schold SC, Fisher B, Schultz CJ, Radiation Therapy Oncology Group Study 93-10. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol. 2002 Dec 15;20(24):4643-8.

191. Jursinic P, Prost R, Schultz C. A new magnetic resonance head coil and head immobilization device for gamma knife radiosurgery: an analysis of geometric distortion and signal/noise characteristics. J Neurosurg. 2002 Dec;97(5 Suppl):563-8.

192. Chang CC, Kampalath B, Schultz C, Bunyi-Teopengco E, Logan B, Eshoa C, Dincer AP, Perkins SL. Expression of p53, c-Myc, or Bcl-6 suggests a poor prognosis in primary central nervous system diffuse large B-cell lymphoma among immunocompetent individuals. Arch Pathol Lab Med. 2003 Feb;127(2):208-12.

193. Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, Kish JA, Kim HE, Cmelak AJ, Rotman M, Machtay M, Ensley JF, Chao KS, Schultz CJ, Lee N, Fu KK, Radiation Therapy Oncology Group 9501/Intergroup. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004 May 06;350(19):1937-44.

194. Souhami L, Seiferheld W, Brachman D, Podgorsak EB, Werner-Wasik M, Lustig R, Schultz CJ, Sause W, Okunieff P, Buckner J, Zamorano L, Mehta MP, Curran WJ Jr. Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. Int J Radiat Oncol Biol Phys. 2004 Nov 01;60(3):853-60.

195. Harris GJ, Woo KI, Schultz CJ, Tayani R, Cancel EM. Late-onset chemosis in patients with head or neck tumors. Ophthalmic Plast Reconstr Surg. 2004 Nov;20(6):436-41.

196. Qi X, Schultz C, Li X. SU‐FF‐T‐369: An Estimation of Radiobiological Parameters From Clinical Outcomes for Radiation Treatment Planning of Brain Tumor Medical Physics. June 2005;32(6):2035-2036.

197. Zhu XR, Schultz CJ, Gillin MT. Planning quality and delivery efficiency of sMLC delivered IMRT treatment of oropharyngeal cancers evaluated by RTOG H-0022 dosimetric criteria. J Appl Clin Med Phys. 2004;5(4):80-95. PMCID: PMC5723523

198. Jursinic PA, Rickert K, Gennarelli TA, Schultz CJ. Effect of image uncertainty on the dosimetry of trigeminal neuralgia irradiation. Int J Radiat Oncol Biol Phys. 2005 Aug 01;62(5):1559-67.

199. Fisher B, Seiferheld W, Schultz C, DeAngelis L, Nelson D, Schold SC, Curran W, Mehta M. Secondary analysis of Radiation Therapy Oncology Group study (RTOG) 9310: an intergroup phase II combined modality treatment of primary central nervous system lymphoma. J Neurooncol. 2005 Sep;74(2):201-5.

200. Chen G, Schultz C, li X. TH‐E‐230A‐05: Development of An Integrated Software Platform for Treatment Documentation and Outcome Analysis for IGRT Medical Physics. June 2006;33(6):2295.

201. Robins HI, Won M, Seiferheld WF, Schultz CJ, Choucair AK, Brachman DG, Demas WF, Mehta MP. Phase 2 trial of radiation plus high-dose tamoxifen for glioblastoma multiforme: RTOG protocol BR-0021. Neuro Oncol. 2006 Jan;8(1):47-52. PMCID: PMC1871929

202. Qi XS, Schultz CJ, Li XA. An estimation of radiobiologic parameters from clinical outcomes for radiation treatment planning of brain tumor. Int J Radiat Oncol Biol Phys. 2006 Apr 01;64(5):1570-80.

203. Wang D, Schultz CJ, Jursinic PA, Bialkowski M, Zhu XR, Brown WD, Rand SD, Michel MA, Campbell BH, Wong S, Li XA, Wilson JF. Initial experience of FDG-PET/CT guided IMRT of head-and-neck carcinoma. Int J Radiat Oncol Biol Phys. 2006 May 01;65(1):143-51.

204. Cardinale R, Won M, Choucair A, Gillin M, Chakravarti A, Schultz C, Souhami L, Chen A, Pham H, Mehta M. A phase II trial of accelerated radiotherapy using weekly stereotactic conformal boost for supratentorial glioblastoma multiforme: RTOG 0023. Int J Radiat Oncol Biol Phys. 2006 Aug 01;65(5):1422-8.

205. Colman H, Berkey BA, Maor MH, Groves MD, Schultz CJ, Vermeulen S, Nelson DF, Mehta MP, Yung WK, Radiation Therapy Oncology Group. Phase II Radiation Therapy Oncology Group trial of conventional radiation therapy followed by treatment with recombinant interferon-beta for supratentorial glioblastoma: results of RTOG 9710. Int J Radiat Oncol Biol Phys. 2006 Nov 01;66(3):818-24.

206. Abrey LE, Ben-Porat L, Panageas KS, Yahalom J, Berkey B, Curran W, Schultz C, Leibel S, Nelson D, Mehta M, DeAngelis LM. Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol. 2006 Dec 20;24(36):5711-5.

207. Li XA, Qi XS, Pitterle M, Kalakota K, Mueller K, Erickson BA, Wang D, Schultz CJ, Firat SY, Wilson JF. Interfractional variations in patient setup and anatomic change assessed by daily computed tomography. Int J Radiat Oncol Biol Phys. 2007 Jun 01;68(2):581-91.

208. Chen GP, Ahunbay E, Schultz C, Li XA. Development of an inverse optimization package to plan nonuniform dose distributions based on spatially inhomogeneous radiosensitivity extracted from biological images. Med Phys. 2007 Apr;34(4):1198-205.

209. Qi XS, Schultz CJ, Li XA. Possible fractionated regimens for image-guided intensity-modulated radiation therapy of large arteriovenous malformations. Phys Med Biol. 2007 Sep 21;52(18):5667-82.

210. Ahunbay E, Schultz C, li X. MO‐E‐AUD C‐05: Can Voxel Based Prescription Dose Be Determined From Multiple Physiological MR Modalities for Brain Tumors? Medical Physics. June 2008;35(6):2876-2877.

211. Ahunbay E, Chen G, Peng C, Schultz C, Li X. TH‐C‐AUD C‐04: An Online Correction Method for Interfractional Variations in Head and Neck Cancer Medical Physics. June 2008;35(6):2972.

212. Vernon MR, Maheshwari M, Schultz CJ, Michel MA, Wong SJ, Campbell BH, Massey BL, Wilson JF, Wang D. Clinical outcomes of patients receiving integrated PET/CT-guided radiotherapy for head and neck carcinoma. Int J Radiat Oncol Biol Phys. 2008 Mar 01;70(3):678-84.

213. Hartford AC, Palisca MG, Eichler TJ, Beyer DC, Devineni VR, Ibbott GS, Kavanagh B, Kent JS, Rosenthal SA, Schultz CJ, Tripuraneni P, Gaspar LE, American Society for Therapeutic Radiology and Oncology, American College of Radiology. American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) Practice Guidelines for Intensity-Modulated Radiation Therapy (IMRT). Int J Radiat Oncol Biol Phys. 2009 Jan 01;73(1):9-14.

214. Parker SM, Olteanu H, VanTuinen P, Lawton CA, Schultz CJ, Christians KK, Fenske TS. Follicular lymphoma transformation to dual translocated Burkitt-like lymphoma: improved disease control associated with radiation therapy. Int J Hematol. 2009 Dec;90(5):616-622.

215. Schultz CJ, Bovi J. Current management of primary central nervous system lymphoma. Int J Radiat Oncol Biol Phys. 2010 Mar 01;76(3):666-78.

216. Siker ML, Firat SY, Mueller W, Krouwer H, Schultz CJ. Semicontinuous low-dose-rate teletherapy for the treatment of recurrent glial brain tumors: final report of a phase I/II study. Int J Radiat Oncol Biol Phys. 2012 Feb 01;82(2):765-72.

217. Zundel MT, Michel MA, Schultz CJ, Maheshwari M, Wong SJ, Campbell BH, Massey BL, Blumin J, Wilson JF, Wang D. Comparison of physical examination and fluorodeoxyglucose positron emission tomography/computed tomography 4-6 months after radiotherapy to assess residual head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2011 Dec 01;81(5):e825-32.

218. Bovi JA, Prah M, Rand SD, SCHULTZ CJ, Schmanda KM. Treatment of recurrent glioblastoma with Bevacizumba with or without re-irradiation using a pulsed-low-dose radietion therapy technique: A single institution experience. Int J Radiat Oncol Biol Phys. 90:S1, Abs #2179, S288.

219. b. Spencer SA, Harris J, Wheeler RH, Machtay M, SCHULTZ C, Spanos W, Rotman M, Meredith R, Ang KK. Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck. Head Neck. Mar;30(3):281-8.

220. b. Spencer SA, Harris J, Wheeler RH, Machtay M, SCHULTZ C, Spanos W, Rotman M, Meredith R, Ang KK . Radiation Therapy Oncology Group 9501/Intergroup. Postoperative concurrent chemotherapy and radiation therapy in high-risk squamous cell carcinoma of the head and neck. N Engl J Med. 350 (19): 1937-1944.

221. Cheng GP, Ahunbay E, SCHULTZ C, Li XA. Development of an inverse optimization package to plan non-uniform dose distributions based on spatially inhomogeneous radiosensitivity extracted from biological images Med Phys. 34(4)April.

222. North L, Stadler M, Massey B, Campbell B, Shukla M, Awan M, Schultz CJ, Shreenivas A, Wong S, Graboyes E, Pipkorn P, Zenga J. Intermediate-grade carcinoma of the parotid and the impact of adjuvant radiation American Journal of Otolaryngology - Head and Neck Medicine and Surgery. November - December 2019;40(6).

223. Conger RL, Mora J, Straza MW, Erickson BA, Lawton CAF, Schultz CJ, Currey A, Bedi M, Siker ML, Hall WA. Evolution in the Presence and Evidence Category of Radiation Therapy Treatment Recommendations in the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology Advances in Radiation Oncology. 1 July 2023;8(4).

224. Raldow AC, Siker ML, Bonner JA, Chen Y, Liu FF, Metz JM, Movsas B, Potters L, Schultz CJ, Wilson E, Wang X, Romero T, Steinberg ML, Jagsi R. Assessment of Differences in Academic Rank and Compensation by Gender and Race/Ethnicity Among Academic Radiation Oncologists in the United States Advances in Radiation Oncology. 1 September 2023;8(5).

225. Schultz CJ, Geard CR. Radioresponse of human astrocytic tumors across grade as a function of acute and chronic irradiation. Int J Radiat Oncol Biol Phys. 1990 Dec;19(6):1397-403.

226. Schottstaedt AM, Paulson ES, Rubenstein JC, Chen X, Omari EA, Li XA, Schultz CJ, Puckett LL, Robinson CG, Alongi F, Gore EM, Hall WA. Development of a comprehensive cardiac atlas on a 1.5 Tesla Magnetic Resonance Linear Accelerator. Phys Imaging Radiat Oncol. 2023 Oct;28:100504. PMCID: PMC10682663

227. Schultz C, et al. Association between locoregional failure and NFE2L2/KEAP1/CUL3 pathway mutations in NRG/RTOG 9512: A Randomized Trial of Radiation Fractionation in T2N0 Glottic Cancer. Submitted to Jnl Clin Oncol, February 2024.

228. Amidon RF, Livingston K, Kleefisch CJ, Martens M, Straza M, Puckett L, Schultz CJ, Mueller WM, Connelly JM, Noid G, Morris K, Bovi JA. Cystic Brain Metastasis Outcomes After Gamma Knife Radiation Therapy. Adv Radiat Oncol. 2024 Jan;9(1):101304. PMCID: PMC10801666

1. SCHULTZ C: T2 Adult Medulloblastoma The Tumor Board: Cancer Diagnosis and Treatment, David P. Winchester, Sr Ed. J.B. Lippincott, Philadelphia, p. 635, December 1996.

2. SCHULTZ C, Whittaker, M: Non-Hodgkin's Lymphoma of the Central Nervous System in a 25-year-old HIV-Positive Man. The Tumor Board: Cancer Diagnosis and Treatment, David P. Winchester, MD, Sr Ed. J.B. Lippincott, Philadelphia, p. 696, December 1996.

3. SCHULTZ C, Gillin M, Mueller W: Modified Linear Accelerator (Linac) Radiosurgery. Radiosurgery Isabelle M. Germano, Ed., AANS Publication Committee, New York, p. 19-30, 2000

4. Shuff JH, Siker ML, Daly MD, SCHULTZ CJ: Role of Radiation Therapy in Cutaneous Melanoma. Cutaneous Melanoma, Clinics in Plastic Surgery, Guest Editor: William Dzwierzynski, WB Saunders, Philadelphia, PA, 37(1)147-160, 2010.

5. SCHULTZ CJ, Bovi JA: Primary Central Nervous System Lymphoma. Principles and Practice of Neuro-Oncology Mehta M, Chang S, Guha, Newton H, M Vogelbaum, Ed. Demos Medical Publishing, New York, p 880-891, 2011.

1. SCHULTZ, CJ: Demonstration of Brachytherapy Boost Dose-Response Relationships in Glioblastoma Multiformae. Int J Radiat Oncol Biol Phys. 35:187-188, 1996.

2. Souhami L, Podgorsak EB, Mehta MP, Brachman D, Werner-Wasik M, Curran Jr WJ, Lustig R, SCHULTZ CJ, Sause W, Okunieff P, Buckner J, Zamorano L: In response to Drs. Vordermark and Kolbl. Int J Radiat Oncol Biol Phys 62(1)p 297, May 2005.

3. Souhami L, Podgorsak EB, Mehta MP, Brachman D, Werner-Wasik M, Curran Jr WJ, Lustig R, SCHULTZ CJ, Sause W, Okunieff P, Buckner J, Zamorano L: In reply to Dr. Kondziolka et al. Int J Radiat Oncol Biol Phys 62(2)p 615-616, June 2005..

4. Abrey L, Ben-Porat L, Panageas K, Yahalom J, Berkey B, Curran W, SCHULTZ C, Liebel S, Nelson D, Mehta M, DeAngeles L. In reply: to Correspondence by Ferreri AJ, Reni M, Zucca E, Cavalli F. Primary CNS lymphomas prognosis. J Clin Oncol 25(27):4322-4; author reply 4324-5, Sep 2007.

1. Mullen EE, SCHULTZ CJ, Swift D, Chang H: The Role of Radiation Therapy in the Postoperative Management of Adult Supratentorial Low Grade Astrocytoma. Int J Radiat Oncol Biol Phys 17: p 234 Suppl 1, 1989.

2. SCHULTZ CJ, Geard CR: Radioresponse of Human Glial Tumors Across Grade as Function of Acute High Dose Rate and Chronic Low Dose Rate Irradiation: Results of an ASTRO Research Fellowship 1988-89. Int J Radiat Oncol Biol Phys 17: Suppl 1 p. 147, 1989.

3. Mullen EE, SCHULTZ CJ, Fisher P, Geard CR: An Evaluation of the Radiation Responsiveness of Human Glioblastoma Cell Lines Expressing the Multidrug Resistant Phenotype. The American Radium Society, Proceedings of the 72nd Annual Meeting, p. 5, 1990.

4. Jacobs JP, Murray KJ, Wilson JF, Cox JD, Goswitz MS, Stevens MD, SCHULTZ CJ: Central Lymphatic Irradiation for Stage III Nodular Lymphoma: An Update. Int J Radiat Oncol Biol Phys 21:160 (Suppl 1), 1991.

5. SCHULTZ CJ, Gaffney DK, Kinsella TK: IdUrd Radiosensitization of Chronically Irradiated Human Glioblastoma Cells. Proceedings of the Fortieth Annual Meeting of the Radiation Research Society, p. 30, 1992.

6. Sharma M, Murray K, Byhardt R, Wilson J, SCHULTZ C: T1 and T2 True Vocal Cord Carcinomas: An Analysis of Clinical and Technical Factors Affecting Local Control by Radiation Therapy. Proceedings of the Third International Conference on Head and Neck Cancer, p. 115, 1992.

7. Campbell BH, SCHULTZ CJ, Brook BJ, Byhardt RW, McAuliffe TJ, Toohill RJ: Preoperative and Postoperative Radiation Therapy for Advanced Squamous Carcinoma of the Head and Neck: A Review of 262 Patients. Middle Section of the Triological Society, Chicago, Illinois, January 1993.

8. SCHULTZ CJ, Davies BM: Confirmation of an Inverse Dose Rate Effect Associated with a G2M Block in Two Human Glioblastoma Cell Lines. Proceedings of the 41st Annual Meeting of the Radiation Research Society, Dallas, Texas, March 20-25, p. 156, 1993.

9. Nelson DF, Scott C, SCHULTZ C, Curran W: The Treatment of Primary Non-Hodgkin's Lymphoma of the Brain. Proceedings of the International Congress of Radiation Oncology 1993 (ICRO '93), Kyoto, Japan, June 21-25, p. 94, 1993.

10. Campbell BH, SCHULTZ CJ, Freije JE, Brook BJ, McAuliffe TL: The Persistently Abnormal Larynx After Radiation Therapy. The American Society for Head and Neck Surgery, Palm Beach, Florida, May 1994.

11. SCHULTZ CJ, Davies BM: G2M Block Characteristics as a Function of Dose Rate in Two Human Glioblastoma Cell Lines. Proceedings of the Radiation Research Society 42nd Annual Meeting, Nashville, TN, April 29 - May 4, p. 177, 1994.

12. Dickson DR, SCHULTZ CJ, Mueller W, Derus S, Gillin M: An Inexpensive, Non-Invasive, Relocatable Head Frame for Fractionated Stereotactic Radiotherapy. Proceedings of the Radiation Research Society 42nd Annual Meeting, Nashville, TN, April 29 - May 4, p. 245, 1994.

13. SCHULTZ C, Scott C, Wasserman T, Fisher B, Abrams R, Sherman W, Fetell M, Nelson J: Pre-Irradiation Chemotherapy (CTX) with Cytoxan, Adriamycin, Vincristine, and Decadron (CHOD) for Primary Central Nervous System Lymphomas (PCNSL): Initial Report of Radiation Therapy Oncology Group (RTOG) Protocol 88-06. Proceedings of the 30th Annual American Society for Clinical Oncology Annual Meeting, Dallas, Texas, May 14-17, p. 174, 1994.

14. Shaw E, Scott C, Souhami L, Dinapoli R, Bahary J-P, Kline R, Wharam M, SCHULTZ C, Davey P, Loeffler J, Del Rose J, Marks L, Fisher B, Shin K: Radiosurgery for the treatment of previously irradiated recurrent primary brain tumors and brain metastases: Initial analysis of Radiation Therapy Oncology Group (RTOG) Protocol 90-05. Int J Radiat Oncol Biol Phys 30 p166, 1994.

15. SCHULTZ C, Mueller W, Zellmer D, Derus S: Semi-continuous Low Dose Rate Teletherapy for the Treatment of Recurrent Glial Brain Tumors: Preliminary Report of a Phase I Study. The American Association of Neurological Surgeons, Orlando, Florida, April 22-27, p. 313, 1995.

16. Freije JE, Beatty TW, Campbell BH, Woodson BT, SCHULTZ CJ, Toohill RJ: Carcinoma of the larynx in patients with gastroesophageal reflux. American Academy of Otolaryngology- Head and Neck Surgery, Desert Springs, Arizona, April 28-May 3, 1995.

17. Auchter RM, Lamond JP, Alexander E, Buatti JM, Chappell RJ, Friedman W, Kinsella TJ, Levin AB, Noyes WR, SCHULTZ C, Loeffler JS, Mehta MP: 8 A multi-institutional outcome and prognostic factor analysis of radiosurgery (RS) for resectable single brain metastasis. Int J Radiat Oncol Biol Phys 32 p145, 1995.

18. SCHULTZ C, Scott C, Wasserman T, Fisher B, Abrams R, Sherman W, Fetell M, Nelson J: Pre-Irradiation Chemotherapy (CTX) with Cytoxan, Adriamycin, Vincristine, and Decadron (CHOD) for Primary Central Nervous System Lymphomas (PCNSL): Initial Report of Radiation Therapy Oncology Group (RTOG) Protocol 88-06. 11th International Conference on Brain Tumor Research and Therapy, Napa, California, October 31- November 3, 1995.

19. Campbell BH, Mark DH, Soneson E, Freije JE, SCHULTZ CJ: The Role of Dental Prosthesis in Alveolar Ridge Squamous Carcinomas. 4th International Conference on Head and Neck Cancer, Toronto, Canada, July 26 - August 1, 1996.

20. Boyd TS, Harari PM, Voytovich MC, Hartig GK, Ford CN, Campbell BH, Foote RL, SCHULTZ CJ: Postradiation Neck Dissection: Indications, Timing, Type of Dissection and Pathologic Findings. 4th International Conference on Head and Neck Cancer, Toronto, Canada, July 26 - August 1, 1996.

21. Corn BW, Dolinskas C, Scott C, Donahue B, SCHULTZ C, Nelson DF, Fisher B. Patterns of Radiographic Response Following Definitive Treatments for Primary Central Nervous System Lymphoma. An Analysis of RTOG Studies 83-15 and 88-06. Presented at the 39th Annual ASTRO Meeting, #2169 Orlando, Florida Oct 19-22, 1997. Int J Radiat Oncol Biol Phys 39(2): p. 325, 1997.

22. Prados M, Scott C, Sandler H, Buckner J, Phillips T, Curran W, SCHULTZ C, Parliameul M, Davis R. Phase III Randomized Study of Radiotherapy with or without PCV for the Treatment of Anaplastic Astrocytoma: RTOG 9404 Interim Report. Presented at the 39th Annual ASTRO Meeting, Orlando, Florida, Oct 19-22, 1997. Int J Radiat Oncol Biol Phys 39(2): p. 14, 1997.

23. SCHULTZ C, Whittaker M, Kolesar P, Donahue B, Fisher B, Nelson D, Vitale C, Hanson G. Incidence of EBV Infection in Primary CNS Lymphoma Occurring in Immunocompetent Patients Treated on RTOG 83-15 and 88-06. Presented at the 39th Annual ASTRO Meeting, Orlando, Florida, October 19-22, 1997. Int J Radiat Oncol Biol Phys, 39 (2): p. 176, 1997.

24. DeAngelis LM, Seiferheld W, Schold SC, Fisher B, SCHULTZ CJ: Combined modality treatment of primary central nervous system lymphoma (PCNSL), Proceedings of the 35th Annual American Society for Clinical Oncology, J Clin Oncol Atlanta, GA, May 15-18, p. 140, 1999.

25. Mehta MP, Meyers CA, Renschler MF, Eisenberg PD, SCHULTZ CJ, Ford JM, Roa WH, Libenhaut M, Arwood D, Cmelak AJ Rao A, Brereton H Timmerman RD Phan SC, DeVault AR, Durran WJ, Gaspar L. 2082 Clinical Trial of Gadolinium Texaphyrin (GD-TEX) in Patients with Brain Metastases. Int J Rad Onco Biol Phys 45(3): p. 320, 1999.

26. Krouwer HG, Kurtin PJ, Ho C, SCHULTZ CJ, Meyer GA: Primary Low-Grade B-Cell Lymphoma of the Dura: More Than an Atypical Primary Central Nervous Lymphoma. The Society of Neuro-Oncology 4th Annual Meeting, Scottsdale AZ, November 18-21, 1999. Neuro-Oncology 1(4): p. 319 October 1999.

27. SCHULTZ, C, Mueller W, Krouwer H, Gillin M, Firat S. Semi-Continuous Low Dose Rate Teletherapy for the Treatment of Glial Brain Tumors: Report of a Phase I/II Study. The Society of Neuro-Oncology 4th Annual Meeting, Scottsdale AZ., November 18-21, 1999. Neuro-Oncology, 1(4): p. 339, October 1999.

28. Mehta MP, Eisenberg P, SCHULTZ CJ, Ford JM, Roa W, Leibenhaut M, Sze G, Einstein S, Renschler MR, Phan SC. Computer Assisted Masked MRI Analysis of Volumetric Response: Implementation for a Phase III Protocol of Gadolinium Texaphyrin (GD-TEX) in Patients with Brain Metastasis. Neuro-Oncology, 1(4): p. 325, October 1999.

29. Meyers CA, Mehta MP, Eisenberg P, SCHULTZ CJ, Ford JM, Roa W, Leibenhaut M, Phan SC, Renschler MF Neurocognitive Impairment in Brain Metastasis Patients, Neuro-Oncology 1(4): p. 326, October 1999.

30. Mehta MP, Meyers C, SCHULTZ C, Ford J, Roa W, Leibenhaut M, Eber D, Phan S, Renschler F. Neurocognitive Function (NF) Predicts Outcome in Patients with Brain Metastases (BM) Treated with Whole Brain Radiation (WBRT) and Xcytrin. Proceedings of Amer Soc Clin Oncol (ASCO) J Clin Oncol 19:164a, 2000.

31. SCHULTZ C, Scott C, DeAngelis L, Nelson D, Nelson J, Schoid Jr C, Curran Jr W. Radiation Therapy (RT) Alone vs Pre-RT Chemotherapy (CTX) for the Treatment of Primary CNS Lymphoma (PCNSL): Age Matched Survival Analysis of RTOG 83-15 and RTOG 93-10. Proceedings of Amer Soc Clin Oncol (ASCO) J Clin Oncol 19:159a, 2000.

32. SCHULTZ C, Scott C, DeAngelis L, Nelson D, Nelson J, Schoid Jr C, Curran Jr W. Radiation Therapy (RT) Alone vs Pre-RT Chemotherapy (CTX) for the Treatment of Primary CNS Lymphoma (PCNSL): Age Matched Survival Analysis of RTOG 83-15 and RTOG 93-10. Presented at RTOG Publications and Scientific Session, June 2000, Montreal, Canada.

33. Mehta MP, Meyers CA, Curran WJ, SCHULTZ CJ, Ford JM, Roa WH, Leibenhaut M, Cmelak AJ, Rao A, Timmerman RD, Gaspar L, Phan SC, Eber D, Renschler MF. XCYTRINTM (motexafin gadolinium) and whole brain radiation for patients with brain metastases: phase II randomized trial - final results. ) Proceedings of the 42nd Annual ASTRO Meeting Int J Radiat Oncol Biol Phys 48(3): Suppl, 204, 2000.

34. Spencer SA, Harris J, Wheeler RH, Machtay M, SCHULTZ C, Spano W, Rotman M, Meredith R. RTOG 96-10 phase I study of reirradiation (RRT) with concurrent hydroxyurea (HU) and 5-fluorouracil (FU) in patients (PTS) with squamous cell carcinoma of the head and neck (SCH&N) Proceedings of the 42nd Annual ASTRO Meeting Int J Radiat Oncol Biol Phys 48(3): Suppl, 177, 2000.

35. SCHULTZ C, Scott C, DeAngelis L, Nelson D, Nelson J, Schoid Jr C, Curran Jr W. Radiation Therapy (RT) Alone vs Pre-RT Chemotherapy (CTX) for the Treatment of Primary CNS Lymphoma (PCNSL): Age Matched Survival Analysis of RTOG 83-15 and RTOG 93-10. Neuro-Oncology 4(2): #198, p. 294, 2000.

36. Sze G, Mehta M, SCHULTZ C, Ford J, Roa WH, Leibenhaut M, Cinelak AJ, Rao A, Timmerman R, Gaspar K, Curran W, Phan SC, DeVault A, Renschler M. Radiologic response evaluation of brain metastases: Uni-dimensional (ID) W.H.O. recist vs bi-dimensional (2D) or 3-dimensional (3D) criteria. Proceedings of the 37th American Society of Clinical Oncology (ASCO) J Clinic Oncol 20 (1): 59a, 2001.

37. Wheeler RH, Harris J, Spencer SA, Machtay M, SCHULTZ C, et al. RTOG 96-10 phase II study of reirradiation (RRT) with concurrent hydroxyurea (HU) and 5-fluorouracil (FU) in patients (PTS) with squamous cell carcinoma of the head and neck: Survival results. Proceedings from Am Soc of Clin Oncol (ASCO) San Francisco CA 2001. J Clin Oncol 222a, 2001.

38. Fisher BJ, Sieferheld W, SCHULTZ C, DeAngelis L, Nelson D, Schold SC, Curran W. Secondary analysis of RTOG 93-10; An intergroup phase II combined modality treatment of primary central nervous lymphoma with chemotherapy and hyperfractionated radiotherapy. Proc of Am Soc Ther Rad Oncol (ASTRO) San Francisco CA 2001 Int J Radiat Oncol Biol Phys 51(3): Supp 1, p.166, 2001.

39. Rodrigus P, Mehta MP, Dehnad H, Rao A, Suh J, Roa W, Souhami L, Bezjak A, Leibenhaut M, Komaki R, SCHULTZ CJ, Timmerman R, Illidge T, Curran WJ, Phan SC, Smith J, Renschler MF: Most troublesome quality of life concerns in patients with brain metastases: baseline results from the phase III trial with motexafin gadolinium. Int J Radiat Oncol Biol Phys 51(3)Suppl 1,P 410, Nov 2001.

40. Yung WK, Seiferheld W, M Groves, SCHULTZ C, Vermeulin S, Nelson D. Conventional radiation followed by recombinant glioblastoma: A RTOG phase II study (RTOG 97-10). Proc of Am Soc Ther Rad Oncol (ASTRO) San Francisco CA 2001 Int J Radiat Oncol Biol Phys 51(3): Suppl 1, p. 206, 2001.

41. Forouzannia A, Sze G, Mehta M, SCHULTZ CJ, Ford JM, Roa WH, Leibenhaut M, Rao A, Cmelak AJ, Timmerman RD: Brain metastases regress isimetrically following radiation, therapy allowing the use of 1D W.H.O. RECIST criteria for adequate response evaluation. Int J Radiat Oncol Biol Phys 51(3)Suppl 1, p 242-243, Nov 2001.

42. Mehta MP, Rodrigus P, Terhaard CH, Rao A, Suh J, Roa W, Souhami L, Bezjak A, Leibenhaut M, Komaki R, SCHULTZ CJ, Timmerman R: Impairment of neurocognitive function in brain metastases patients: baseline results from the phase III trial with motexafin gadolinium. Int J Radiat Oncol Biol Phys Abs #242 51(3):135-136, 2001.

43. Prados M, Scott C, Sandler H, Buckner, Phillips T, SCHULTZ C, Urtasun R, Davis R, Gutin P, Greenberg H. RTOG 94-04: A phase III randomized study of radiotherapy plus Procarbazine, CCNU, and Vincristine (PCV) with or without BudR for the treatment of anaplastic astrocytoma. Proc of Am Soc Ther Rad Oncol (ASTRO) San Francisco CA 2001 Int J Radiat Oncol Biol Phys 51(3): Suppl 1, p. 207, 2001.

44. Souhami L, Scott C, Brachman D, Podgorsak E, Werner-Wasik M, Lustig R, SCHULTZ CJ, Sause W, Okunieff P, Buchner J, Zamorano L, Curran W. Randomized Prospective Comparison of Stereotactic Radiosurgery (SRS) Followed by Conventional Radiotherapy (RT) with BCNU to RT with BCNU Alone for Selected Patients with Supratentorial Glioblastoma Multiforme (GBM): Report of RTOG 93-05 Protocol. Int J Radiat Oncol Biol Phys 54(2): Suppl 1, p. 94-95 2002.

45. Cooper JS, Pajak TF, Forastiere A, Jacobs J, Saxman SB, Kish, J, Kim HE, Cmelak A, Rottman M, Machtay M, Ensley JF, Chao C, SCHULTZ CJ, Lee N, Fu KK. Patients of Failure for Resected Advanced Head & Neck Cancer Treated by Concurrent Chemotherapy and Radiation Therapy: An Analysis of RTOG 95-01. Int J Radiat Oncol Biol Phys 54(2): Suppl 1, p 2 2002.

46. Zhu R, SCHULTZ C, Jursinic P, Gillin M. IMRT Treatment Planning for Static MLC Delivery: Impact of number of Gantry Angles and Levels of Modulation on Quality and Efficiency of Head and Neck IMRT Delivered per RTOG H-0022. Int J Radiat Oncol Biol Phys 54(2): Suppl 1, p. 320, 2002.

47. Curran WJ, Mehta M, Rodrigus P, Terhaard C, Rao A, Suh J, Roa W, Souhami L, Bezjak A, Leibenhaut M, Komaki R, SCHULTZ C, Timmerman R, Illidge T, Phan S, Smith J, DeVault A Miller R, Renschler MR. Predictors of Survival for Patients with Brain Metastases: Results of a Randomized Phase III Trial, Proceedings of the ASTRO 44th Annual Meeting, Int J Radiat Oncol Biol Phys 54(2): Suppl p. 93, Abs #155, 2002.

48. SCHULTZ CJ, Prost, R, Jursinic P, Krouwer, H, et al: A Novel MR Head Coil/Head Immobilizer for Gamma Knife Radiosurgery: 11th International Meeting of the Leksell GammaKnife Society, Prague,Czech Republic, May 12-16, 2002.

49. Mehta MP, Rodrigus P, Terhaard C, Rao A, Suh J, Roa W, Shapiro W, Glantz MJ, Patchell R, Weitzner M, Souhami L, Bezjak A, Leibenhaut M, Komaki R, SCHULTZ C, Timmerman R, Illidge T, Meyers C, Curran WJ, Phan S, Smith J, Miller R, Renschler MF. Results from the phase III trial of motexafin gadolinium (MGd) in brain metastases. Proceedings from Am Soc Clin Oncol (ASCO) Orlando FL, J Clin Oncol 21: p. 72a, Abs #286, 2002.

50. Cooper JS, Pajak TF, Forastiere A, Jacobs J, Saxman SB, Kish J, Kim HE, Cmelak A, Rottman M, Achtay M, Ensley JF, Chao C, SCHULTZ CJ, Lee N, Fu KK. Postoperative Concurrent Radiochemotherapy in High-Risk SCCA of the Head & Neck: Initial Report of RTOG 95-01/ Intergroup Phase III Trial. Proceedings from Am Soc Clin Oncol (ASCO), Orlando FL J Clin Oncol 21: p. 226a, 2002.

51. Terhaard C, Mehta, MP, Rodrigus P, Rao A, Suh J, Roa W, Souhami L, Bezjak A, Leibenhaut M, Komaki R, SCHULTZ C, Timmerman R, Illidge T, Meyers C, Curran WJ, Phan SC, Smith J, Renschler MF. Quality of life (QOL) in patients with brain metastases is strongly related to MRI tumor volume and neurocognitive function (NCF): baseline results from the phase III trial of motexafin gadolinium (MGd). Proceedings from Am Soc Clin Oncol (ASCO) Orlando FL, J Clin Oncol 21: p. 73a, Abs #290, 2002.

52. Rodrigus P, Mehta, MP, Terhaard C, Rao A, Suh J, Roa W, Souhami L, Bezjak A, Leibenhaut M, Komaki R, SCHULTZ C, Timmerman R, Illidge T, Meyers C, Curran WJ, Phan SC, Smith J, MF Renschler MF. Impaired neurocognitive function (NCF) in brain metastasis patients is strongly correlated with MRI tumor volume and tumor histology: baseline results from the phase III trial of motexafin gadolinium (MGd) baseline results from the phase III trial of motexafin gadolinium (MGd). Proceedings from Am Soc Clin Oncol (ASCO) Orlando FL, J Clin Oncol 21: p. 74a, Abs #292, 2002.

53. Miles D, Ford J, Mehta MP, SCHULTZ C, deBower P, Dehnad H, Roa A, Suh J, Roa W, Timmerman R, Souhami L, Bezjak A, Leibenhaut M, Komaki R, Hutcheson S, Boswell G, Phan SC, Renschler MF. An evaluation of gender, alkaline phosphatase, and cytochrome P450 on motexafin gadolinium pharmacokinetics in patients with brain tumors using a population pharmacokinetic analysis. Proceedings from Am Soc Clin Oncol (ASCO) Orlando FL, J Clin Oncol 21: p. 119a, Abs #474, 2002.

54. Mehta M, Rodrigus P, Terhaard C, Rao A, Suh J, Roa W, Shapiro W, Glantz M, Patchell R, Weitzner M, Souhami L, Bezjak A, Leibenhaut M, Komaki R, SCHULTZ C, Timmerman R, Illidge T, Meyers C, Curran W, Phan S, et al. Motexafin Gadolinium Prolongs Time to Neurologic Progression in Lung Cancer Patients with Brain Metastases: Results of a Randomized Phase III Trial. Proceedings of the ASTRO 44th Annual Meeting, Int J Radiat Oncol Biol Phys 54(2): Suppl p. 92, Abs #154, 2002.

55. Spencer SA, Harris J, Wheeler RH, Machtay M, SCHULTZ CJ, Spanos W, oman M, Meredith R, Ang K: Late Effects of RTOG 96-10. Re-irradiation and Chemotherapy in Patients with Squamous Cell Cancer of the Head and Neck. Proceedings of the 45th Annual ASTRO Meeting, Int J Radiat Oncol Biol Phys 57(2):Suppl 1, p S307, Abs #1077, 2003.

56. Robins HI, Won M, SCHULTZ C, Choucair A, Brachman D, Demas W, Mehta M. A phase II trial of conventional radiation therapy (XRT) plus high dose tamoxifen (TAM) for the treatment of supratentorial glioblastoma multiforme (GBM): RTOG protocol BR-0021. Proceedings from Am Soc Clin Oncol (ASCO) New Orleans LA, J Clin Oncol 23: p. 114, Abs #1529, 2004.

57. Choucair AK, Seiferheld W, Ford C, Hansen J, Dabbas C, SCHULTZ C, Schulsinger A, Mehta M, Curran W. Long Term Survivors with Glioblastoma Multiforme (GBM) treated on RTOG protocols with Irradiation and Nitrosourea have a higher expression of Ki-67. Proceedings from Am Soc Clin Oncol (ASCO) New Orleans LA, J Clin Oncol 23: p. 871, Abs #9661, 2004.

58. Ford C, Seiferheld W, Chouccair A, Hansen J, Dabbas B, SCHULTZ C, Schulsinger A, Mehta M, Curran W. Expression of DNA repair molecules is not a significant prognostic factor for long term survivors with glioblastoma multiforme (GBM) treated on RTOG protocols with irradiation and BCNU. Proceedings from Am Soc Clin Oncol (ASCO) New Orleans LA, J Clin Oncol 23: p. 109, Abs #1509, 2004.

59. Jursinic P, Rickert K, Gennarelli T, SCHULTZ C. Effect of Image Uncertainty on the Dosimetry of Trigeminal Neuralgia Irradiation: Proceedings 12th International Meeting of the Leksell GammaKnife Society, Vienna, Austria May 16-18, p. 243, 2004.

60. Gabayan A, Sanan A, Lachaine M, Woolfenden J, Stea B, SCHULTZ, C: GliaSite radiotherapy system for treatment of recurrent malignant glioma: a multi institutional analysis: ESTRO Joint Brachytherapy Meeting GEC/ESTRO-ABS-GLAC Proceedings, Radiother Oncol 60 (1) Supp2 p. S62 Abst #125, 2004.

61. Rosenthal DL, Harris J, Forastiere AA, Weber RS, Ridge JA, Myers JN, Garden AS, Kuettel M, Sidhu K, SCHULTZ C, Ang KK: Early Postoperative Paclitaxel Followed by Paclitaxel and Cisplatin Concurrent with Radiation Therapy (RT) (Phase II Trial RTOG H-0024) is Well Tolerated for Patients with Resected, High-Risk Squamous Carcinoma of the Head and Neck (HNSCC) (Proceedings of the ASTRO 44th Annual Meeting, Int J Radiat Oncol Biol Phys 60(1) Suppl,p S322, Sept 2004.

62. Wang D, Bialkowski M, SCHULTZ C, Jursinic P, Zhu Z, Brown D, Rand S, Nalwa S, Campbell B, Li A: FDG-PET/CT Guided Intensity Modulated Radiation Treatment for Head and Neck Carcinoma. Proceedings of the ASTRO 44th Annual Meeting, Int J Radiat Oncol Biol Phys 60:1 Supp S519, Abs #2305, 2004.

63. Qi XS, SCHULTZ CJ,Li XA: SU-FF-T-369: An Estimation of Radiobiological Parameters from Clinical Outcomes for Radiation Treatment Planning of Brain Tumors, AAPM Annual Meeting, Seattle, WA, 7/24/2005 - 7/28/2005. Med Phys. 32(6)#2035, 2005.

64. Li XA, Ahunbay E, Qi XS, SCHULTZ C: Planning Non-uniform Dose Distributions for Brain Tumor, AAPM Annual Meeting, Seattle, WA, 7/24/2005 - 7/28/2005. Med Phys 32,#2038, 2005.

65. Cardinale R, Won M, Choucair A, Gillin M, Chakravarti A, SCHULTZ C, et al: A phase II trial of accelerated radiotherapy using weekly stereotactic conformal boosts for supratentorial glioblastoma multiforme. RTOG 0023. J Clin Oncol 23:16S Abs #1511, p116s, 2005.

66. Shaw EG, Won M, Brachman DG, SCHULTZ CJ et al: Preliminary results of RTOG protocol 9802. A phase II study of observation in completely resected adult low-grade glioma. World Federation of Neuro-Oncology Meeting Abs #7, Edinburgh, Scotland, May 5-8, 2005.

67. Vogelbaum MA, Berkey B, Peereboom D, Giannini C, Suh J, Brown P, Blumenthal D, Biggs C, SCHULTZ C, Mehta M: RTOG 0131: Phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligodendrogliomas. ASCO Meeting Abstracts May 28, 2005:1520, 2005.

68. Ahunbay E, Schmainda K, Lund R, Prost R, Ulmer J, Alaly J, Deasy J, SCHULTZ C, Li X: SU-FF-J-105: Tools for Voxel-By-Voxel Correlation of Radiotherapy Dose and MR Signals From Multiple Physiological/functional MRI Modalities. Med Phys 32(6), 2005.

69. Lund R, Rand S, Krouwer H, SCHULTZ C, Schmainda K: Using rCBV to Distinguish Radiation Necrosis from Tumor Recurrence in Malignant Gliomas. Int J Radiat Oncol Biol Phys -Abs #108 63(2) supp S65, 2005.

70. Qi X, SCHULTZ CJ, Li X: Possible Fractionation Regimens for the Treatment of Large-size Arteriovenous Malformation Using IMRT. Int Journ Radiat Oncol Biol Phys Abs #2404 63(2) supp S470, 2005

71. Call JA, Wang D, Firat S, Byhardt RW, Wong S, Campbell B, SCHULTZ C: P129 Toxicity Outcomes in Intensity-Modulated Radiation Therapy vs 3-Dimensional Conformal Radiotherapy for Head and Neck Squamous Cell Carcinoma with Unknown Primary, Arch Otolaryngol Head and Neck Surg 132:890, 2006

72. Li X, Qi X, Mueller K, Jursinic P, Erickson B, Wang D, SCHULTZ C, Firat S, Wilson J: SU-FF-J-122: Systematic Study of Inter-Fractional Variations for Anatomic Sites From Head to Feet. Med Phys 33(6)01, 2006.

73. Chen G, SCHULTZ C, LI, XA: Development of an Integrated Software Platform for Treatment Documentation and Outcome Analysis for IGRT, AAPM Annual Meeting, Orlando, FL, 7/30/2006 - 8/3/2006. Med Phys 33, #2295, 2006.

74. Chakravarti A, Berkey B, Robins H, Guha A, Curran W, Brachman D, SCHULTZ C, Mehta M: An Update of Phase II Results of RTOG 02-11: A Phase I/II Study Gefitinib + Radiation for Newly Diagnosed Glioblastoma Patients. J Clin Oncol Vol 24, No 18S:1527, 2006.

75. Eisbruch A, Harris J, Garden A, Chao C, Straube W, SCHULTZ C, Sangiuneti G, Jones C, Bosch W Ang KK. Phase II Multi-Institutional Study of IMRT for Oropharyngeal Cancer (RTOG 00-22) Early Results. Int J Radiat Oncol Biol Phys 66:3S, Abs #79, S46, 2006.

76. Li XA, Qi A, Mueller K, Jursinic PA, Erickson, BA, Wang D, SCHULTZ C, Firat SY, Wilson JF. Inter-Fractional Variations in Patient Setup and Anatomic Change Assessed by Daily CT from Helical Tomotherapy. Int J Radiat Oncol Biol Phys 66:3S, Abs #2739, S621, 2006.

77. Chen GP, Ahunbay E, SCHULTZ C, Li XA: Design of non-uniform dose distribution based on spatially inhomogeneous radiosensitivity extracted from biological images, Int J Radiat Oncol Biol Phys 66(3)suppl 1,p S717-S718, Nov 2006.

78. Wang D, SCHULTZ C, Michel M, Wong S, Campbell B: Is FDG-PET/CT Valuable in Assessment of Tumor Response Following Radiation Treatment for Head and Neck Carcinomas? Int J Radiat Oncol Biol Phys 66(3)Suppl 1,pS421, Nov 2006.

79. Qi XS, Li XA, Kainz K, Brammer B, Olivera GH, Ruchala KJ, SCHULTZ C, Wilson JF: Ranking complex IMRT plans using an EUD-based figure-of-merit index. Int J Radiat Oncol Biol Phys 66(3)Suppl 1,p S658, Nov 2006.

80. Glass J, Berkey B, SCHULTZ CJ: RTOG 02-27: Phase I/II Study of Pre-irradiation Chemotherapy with Methotrexate, Rituximab and Temozolomide and Post-irradiation Temozolomide for Primary Central Nervous System Lymphoma. Neuro Oncol October, 8(4):443, 2006.

81. Abrey LE, Ben-Porat L, Panageas KS, Yhhalom J, Berkey B, Curran W, SCHULTZ C, Leibel S, Nelson D, Mehta M, DeAngelis LM: Primary Central Nervous System Lymphoma: The Memorial Sloan-Kettering Cancer Center Prognostic Model. J Clin Oncol 5711-5715 Dec 20, 2006.

82. Garden A, Tishler R, Barasch A, Brennan M, Harari P, Kudrimoti M, SCHULTZ C, Brachman DB, Vera-Lionch M, Keefe D. Adverse Impact of Mucositis on Health Related Quality of Life Outcomes and Resource Use in Head and Neck Cancer Patients Receiving Radiation. Int J Radiat Oncol Biol Phys 69(3): S179-180, 2007.

83. Kainz K, Wilson JF, SCHULTZ C, Jursinic P, Li XA: Image-Guided Helical Tomotherapy to Treat Advanced Cancers of the Scalp: Prospects for Dose Conformity and Clinical Outcome, AAPM Annual Meeting, Minneapolis, MN, 7/22/2007 - 7/26/2007. Med Phys 34,#2576, 2007.

84. Li X, Stewart R, Semenenko V, Qi S, Chen G, Ahunbay E, SCHULTZ C: SU-FF-T-54: A Three-Phase Strategy for a Partial Implementation of Biologically Guided Radiation Therapy. Med Phys 34(6), 2007.

85. Ahunbay E, SCHULTZ C, Li X: MO-E-AUD C-05: Can Voxel Based Prescription Dose Be Determined From Multiple Physiological MR Modalities for Brain Tumors?. Med Phys 35(6), 01/2008.

86. Ahunbay E, Chen G, Peng C, SCHULTZ C, Li X: TH-C-AUD C-04: An Online Correction Method for Interfractional Variations in Head and Neck Cancer. Med Phys 35(6), 2008.

87. Zundel T, Michel M, SCHULTZ C, Maheshwari M, Wong S, Campbell B, Massey B, Blumin J, Wilson JF, Wang D: High negative predictive value of FDG-PET/CT in assessment of tumor response following radiation treatment for head and neck carcinoma. Poster presentation ASTRO Sept 20-24, 2008, Boston MA

88. Siker ML, Firat S, Mueller WM, SCHULTZ CJ: Semi-continuous Low Dose Rate (LDR) Teletherapy for the Treatment of Recurrent Glial Brain Tumors: Final Report of a Phase I/II Study. Int J Radiat Oncol Biol Phys 72(1)Suppl 1, PS234, Sept 2008.

89. Semenenko VA, Qi XS, Daly MD, SCHULTZ CJ, Li XA: Dosimetric Comparison between Head and Neck IMRT Plans Generated using a Biologically-based and Dose-based Treatment Planning Systems. Int Journ Radiat Oncol Biol Phys Abs #2961 72(1) supp S600, 2008.

90. Wood C, Ahunbay E, Peng C, Wang D, SCHULTZ C, Li XA, Quantifying Interfractional Variations for Head and Neck Cancer Treatment Based on Daily kVCT to Determine Selection Criteria for Adaptive Correction Schemes, ASTRO Annual Meeting, Boston, MA, 9/21/2008 - 9/25/2008. Int J Radiat Oncol Biol Phys. 72:1, Supplement 1,p S599, Sep 2008.

91. Wang D, Michel M, Campbell B, Massey B, Blumin J, Wong S, SCHULTZ C: High Negative Predictive Value of FDG-PET/CT in Assessment of Tumor Response Following RT of SCCHN. International Journal of Radiation Oncology Biology Physics -Int J Radiat Oncol Biol Phys Abs #2499 72(1) supp S392, 2008.

92. Choucari A, Moughan J, Ford C, Hansen J, SCHULTZ C, Schulsinger A, Hammond E, Mehta M, Curran W. Predictive value of HMLH1 after adjusting for RPA class in patients with GBMs treated on RTOG protocols. 13th Annual Meeting of the Society of Neuro-Oncology, Neuro-Oncology 10:5, Abs #PA-06, p855, Oct 2008

93. Kainz K, Wilson JF, SCHULTZ C, Hu B, Bagley J, Li XA: Image-guided IMRT for Advanced -staged Skin Cancer Patients: Margin Reduction and Clinical Outcome. Int J Radiat Oncol Biol Phys 75:3S, Abs #3189, S716, 2009.

94. Chen G, Hu B, Qi S, SCHULTZ C, Wang D, Li X: SU-FF-T-591: Improvement of IMRT Plan Quality with Non-Isocentric Beam Arrangement for Head and Neck Cancers. Med Phys 36(6) p2660, 2009.

95. Wang K, Peng C, Qi SX, Wong S, Campbell B, Wang D, SCHULTZ C, Li XA: Correlation of Interfractional Anatomic Changes of Tumor and Salivary Glands with Acute Toxicities in Radiotherapy for Head and Neck Cancer. Fuel and Energy Abstracts 75(3) S417, 2009.

96. Bradley JA, Paulson ES, Ahunbay E, Li XA, SCHULTZ C, Wang D: Dynamic MRI Analysis of Tumor Motion during Deglutition and Intrafraction Margin Assessment for Radiotherapy of Head-and-Neck Cancer. Presented at ASTRO, Chicago IL 2009

97. Marwaha A, Choong NW, Firat S, SCHULTZ CJ, Wang D, Wong SJ: Clinical efficacy and tolerability of continuous course reirradiation with concurrent weekly carboplatin-paclitaxel for locally recurrent, nonmetastatic squamous cell carcinoma of the head and neck (SCCHN). Proceedings from Am Soc Clin Oncol (ASCO) 28:15S, Abs #5518, p425s, 2010.

98. Firat S, Siker ML, SCHULTZ CJ, Jogal SS, Kaufman BA, Stratton JJ, Murray KJ: Supine Craniospinal Irradiation (SCI) in Medulloblastoma (MBL): Long-term Outcomes. Int J Radiat Oncol Biol Phys Abstracts 78(3) supp S589, 2010.

99. Charkravarti A, Wang M, Robins I, Guha A, Curren W, Brachman D, SCHULTZ C, et al: Determinants of therapeutic resistance in glioblastomas: Lessons learned from the RTOG 02-11. Neuro-Oncology, Vol 12(4), November 2010.

100. Bedi M, Firat S, Semenenko V, SCHULTZ C, Tripp P, Byhardt R, Wang D: Is Conventional Dose and Fractionation Required to Prophylactically Treat Neck Lymphatics for Head and Neck Cancer Treated with IMRT?. Int J Radiat Oncol Biol Phys 78:3 supp S153-S154 Nov 2010.

101. SCHULTZ CJ, Kinsella TK: IdUrd Radiosensitization of Human Glioblastoma Cells Exposed to Acute and Chronic Gamma Irradiation. Editors: Chapman J D, Dewey W C, and Whitmore GF. International Congress of Radiation Research, A Twentieth-Century Perspective. Presented 7/7-7/12/11, Toronto, Canada.

102. Modelska K, Adkins D, Suen J, Pathare P, SCHULTZ C, Hu K, Epstein J, Zhen W, Tuthill C, Rios I, Sonis S on behalf of the SCV-07 Clinical Trials Study Team. Development of γ-D-glutamyl-L-tryptophan (SCV-07) for the treatment of oral mucositis. Support Care Cancer, 19 (Suppl 2):S67–S370, 2011.

103. Kish JA, Zhang Q, Langer CJ, Nguyen-Tan F, Rosenthal DI, Weber RS, List M, Wong S, Garden AS, Cooper J, Trotti A, Bonner J, Jones CU, Yom SS, Michalski JM, Schultz C, Ridge JA, Shenouda G, Le QT. The Influence of Age on Outcome in Prospective, Phase III NRG Oncology/RTOG Trials of Radiotherapy (XRT)+/- Systemic Therapy in Locally Advanced (LA) Head and Neck Cancer (HNC). J Clin Onc 33, No 15 Suppl Abs#6003, May 2015

104. Gilbert MR, Wang M, Aldape D, Stupp R, Hegi M, Jaeckle A, Armstrong TS, Wefel JS, Won M, Blumenthal DT, Mahajan A, SCHULTZ CJ, Erridge SC, Brown PD, Chakravarti A, Curran WJ, Metha MP. RTOG 0525: A randomized phase III trial comparing standard adjuvant temozolomide (TMZ) with a dose-dense (dd) schedule in newly diagnosed glioblastoma (GBM). J Clinic Oncol, 289(15), May 20 supp:2006, 2011.

105. Bell E, SCHULTZ C, et al. Predictive Significance of IDH1/2 Mutation and 1p/19q Co-Deletion Status in a Post-Hoc Analysis of NRG Oncology/RTOG 9802: A Phase III Trial of RT vs RT + PCV in High Risk Low Grade Gliomas. Presented at Society of Neuro Oncology Annual Meeting, San Francisco, CA, November 16-19, 2017

106. Aldape KD, Wang M, Sulman EP, Hegi M, Colman H, Jones G, Chakravarti A, Mehta MP, Andrews DW, Long L, Diefes K, Heathcock L, Jenkins R, SCHULTZ CJ, Gilbert MR and Radiation Therapy Oncology Group. RTOG 0525: Molecular correlates from a randomized phase III trial of newly diagnosed glioblastoma. J Clinic Oncol 29(18) June 20 supp, LBA2000, 2011.

107. Camphausen K, Wang M, Graves C, Corn B, Muanza T, Howard S, Mahajevan A, SCHULTZ C, Haas M, Mehta M: Predictive value of tumor recurrence using urinary vacular endothelial growth factor levels in patients receiving radiation therapy for glioblastoma RTOG 0611. (Poster presented at ASTRO Oct 2 - 6, 2011 Miami Beach, FL). Int J Radiat Oncol Biol Phys 81(2)Suppl 1, P S181, Oct 2011.

108. Yang C, Lin F, Cheng E, Lawton C, Wang D, SCHULTZ C, Firat S, Erickson B, Li XA: Using an online adaptive replanning tool for offline adaptive radiotherapy Int J Radiat Oncol Biol Phys 81(2) Supplement Abs #3340 S850, 2011.

109. Bradley J, Paulson E, Wang D, Wong S, SCHULTZ C, Campbell B, Massey B, Li A: MRI analysis of changes in tumor characteristicsin patients with head and neck squamous cell carcinoma treated with concomitant chemoradiation (Poster accepted at the Multidisciplinary Head and Neck Symposium, Arizona 1/12)

110. Cooper JS, Zhang Q, Forastiere AA, Jacobs J, Saxman B, Kish A, Cmelkak AJ, Ensley JF, SCHULTZ CJ, Yom SS: Long term follow up of the RTOG 9501/Intergroup phase III trial: Postperative concurrent radiation therapy and chemotherapy in high risk squamous cell carcinoma of the head and neck (Submitted to ASTRO/ASCO 2012)

111. Rios I, Alexander WJ, Karlin DA, Sonis ST, Tuthill CW, Kudrimoti MR, Zhen W, Adkins D, Bienvenu BJ, SCHULTZ CJ, Suen JY, Kim H, Chen Y, Katz SR, Venigalla ML, Hu K, Pathare PM, Witherby SM, Miyamoto MC, Schwartz DL; Phase 2b study evaluating efficacy and safety of gamma-D-glutamyl-L-tryptophan in attenuation of oral mucositis during chemoradiation in head and neck cancer patients. (Submitted to ASCO 2012 "Trials in Progress")

112. Chakravarti A, Wang M, Aldape K, Sulman E, Bredel M, Magliocco A, Klimowicz A, Hegi M, Stupp R, Gilbert M, Curran W, Werner-Wasik M, Mahajan A, SCHULTZ C, Mehta M. A revised RTOG recursive partitioning analysis (RPA) model for glioblastoma based upon multi-platform biomarker profiles. Oral Presentation at ASCO 2012

113. Li XA, Yang C, Liu F, Ahunbay E, Chang Y, SCHULTZ C, Wang D, Firat S, Erickson B, Lawton C, Combined online and offline adaptive radiation therapy, ASTRO 54th Annual Meeting, Boston, MA, 10/28/2012 - 10/31/2012. Int J Rad Onc Bio Phys 84:3, Supplement 1 Abs #71, p S29-S30, Nov 2012.

114. Wang D, Michel M, Bedi M, Campbell BH, Massey B, Wong S, SCHULTZ CJ. High Negative Predictive Value of FDG-PET/CT in Assessment of Tumor Response Following Radiation Treatment for Head and Neck Carcinomas: Long-term update Poster presented at ASTRO 2012. Int J Radiat Oncol Biol Phys 84:3S Abs #2810 S520, 2012.

115. Bradley J, Paulson ES, Kharofa J, Li XA, SCHULTZ C, Wang D. Patient and Tumor Characteristics and Pre-Treatment Swallowing Frequency and Duration in Head and Neck Cancer Patients Int J Radiat Oncol Biol Phys 84:3S Abs #2786, S512, 2012.

116. Kainz K, Firat S, SCHULTZ C, Wilson JF, LI XA, Plan quality of proton vs. photon IG-IMRT, ASTRO 54th Annual Meeting, Boston, MA, 10/28/2012 - 10/31/2012. Int J Radiat Oncol Biol Phys, 84:3, S 1,S837-S838, Nov 2012.

117. Ahunbay E, Kimura B, SCHULTZ C, Li XA: Adaptive replanning considering previously delivered dose for head and neck cancers. Int J Radiat Oncol Biol Phys 84:3S Abs #3558 S804, 2012.

118. Yi J, Ahunbay E, Li Z, SCHULTZ C, Wang D: Significant reduction of salivary gland volumes after the first two-week standard fractionation IMRT for head and neck cancer. Int J Radiat Oncol Biol Phys. Abs #2619 87(2) supp pS440, 2013.

119. Leo P, Franczak M, Beentsen S,Bovi J, LaViolette P, SCHULTZ C, Sabsevitz D: A quantitative study of cerebral atrophy following whole brain radiation therapy. Poster presentation at American Academy of Clinical Neuropsychology AACN 6/13.

120. Glass J, Won M, SCHULTZ C, et al: Preirradiation chemotherapy with methotrexate, rituximab, and temozolomide and post-irradiation temozolomide for primary central nervous system lymphoma: RTOG 0227 phase II study results. J Clin Oncol 3115 Supp Abs #2033, 2013.

121. Kainz K, Wang WA, Firat S , Wilson JF, SCHULTZ C, Li XA, Plan quality of proton vs. photon IMRT for whole ventricle irradiation, AAPM Annual Meeting, Indianapolis, IN, 8/4/2013 - 8/8/2013. Med Phys 40, #380, 2013.

122. Tai A, SCHULTZ C, Li XA: Extracting patient specific radiobiological parameters from tumor regression for biologically-based adaptive radiation therapy of head and neck cancer, AAPM Annual Meeting, Indianapolis, IN, 8/4/2013 - 8/8/2013. Med Phys 40,#379, 2013.

123. Chen X, Botros M, Ahunbay E, Wang D, SCHULTZ C, Li XA, Interfractional Dose Variations in Parotid and Submandibular Glands in IG-IMRT for Head and Neck Cancer, AAPM Annual Meeting, Austin, TX, 7/20/2014 - 7/24/2014. Med Phys 41,#402, 2014.

124. Buckner JC, Pugh SL, Shaw EG, Gilbert MR, Barger G, Coons S, Ricci P, Bullard D, Brown PD, Stelzer K, Brachman D, Suh JH, SCHULTZ CJ, Bahary J-P, Fisher BJ, Kim H, Murtha AD, Curran WJ, Mehta MP: Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine (PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. J Clin Oncol 32:15 May supp, Abs #2000, ASCO 2014. .

125. Elson A, Bovi JA, Paulson E, SCHULTZ C: Evaluation of Pre-Radiation Therapy Apparent Diffusion Coefficient (ADC): Patterns of Recurrence and Progression-Free Survival Analysis in Patients With GBM. Int J Radiat Oncol Biol Phys 90(1) Supp 1,p S282-S283, Sept 2014.

126. Mei F, Yang C, Xu S, Moraru I, SCHULTZ C, Li XA: CT number changes observed during CT-guided radiotherapy for head and neck cancer, a new indicat#or for treatment response. Int J Radiat Oncol Biol Phys 90:S1, Abs #3635, S853, 2014.

127. Straza M, Friedland D, Bovi J, SCHULTZ C: Gamma Knife Radiosurgery for Acoustic Neuroma: A single institution experience. Presented at the Soceiety of Neuro-Oncology (SNO) Nov 2014

128. Mehta MP, Won M, Shaw EG, Buckner J, Gilbert M, Barger G, Coons S, Ricci P, Bullard D, Brown P, Stelzer K, Brachman D, SuH JH, SCHULTZ C, et al: Mature survival outcomes data from RTOG 9802: A phase III study of radiation therapy (RT) with or without procarbazin, CCNU, and vincristine (PCV) for adult patients with high-risk low-grade glioma (LGG). Int J Rad Onc Biol Phys 90:S1 Suppl,Abs #74, S37, 2014.

129. Buckner JC,Pugh SL, Shaw EG, Gilbert MR, Barger G, Coons S, Ricci P, Bullard D, Brown PD, Stelzer K, Brachman D, Suh JH, SCHULTZ CJ, Bahary JP, Fisher BJ, Kim H, Murtha AD, Curran Jr WJ, Mehta MP: Long term results of R9802: A Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine (PCV) in low-grade glioma. RTOG with Alliance, ECOG-ACRIN and SWOG. Presented at Society of Neuro Oncology (SNO) Nov 2014.

130. Bovi JA, Prah M, Rand SD, SCHULTZ CJ, Schmanda KM: Treatment of recurrent glioblastoma with Bevacizumba with or without re-irradiation using a pulsed-low-dose radietion therapy technique: A single institution experience. Int J Radiat Oncol Biol Phys 90:S1, Abs #2179, S288, 2014.

131. Chen X, Prior P, SCHULTZ C, Li XA: The dose effect of transverse magnetic field on IMRT plans delivered in a MR-Linac. Int J Radiat Onc Biol Phys, 90 S1, Abs #210 S98, 2014.

132. Chang SM, Zhang P, Cairncross JG, Gilbert MR, Bahary J-P, Dolinskas C, Aldape KD, Chakravarti A, Schiff D, Jaeckie KA, Brown PD, Barger G, Werner-Wasik M, Shih HA, Brachman D, Penas-Prado M, Robins HA, Belanger K, SCHULTZ CJ, Mehta MP: Results of NRG Oncology/RTOG 9813- A Phase III Randomized Study of Radiation Therapy (RT) and Temozolomide (TMZ) versus RT and Nitrosourea (NU) therapy for Anaplastic Astrocytoma. Presented at 2015 ASCO Annual Meeting, 33:15 May 20, 2015 May 29-June 2, 2015:2002

133. Kish JA, Zhang Q, Langer CJ, Nguyen-Tan F, Rosenthal DI, Weber RS, Lisa MA, Wong SJ, Garden AS, Cooper JS, Trotti A, Bonner JA, Jones CU, Yom SS, Michalski JM, SCHULTZ CJ, Ridge JA, Shenouda G, Le Q-T. The effect of age on outocme in prospective, phase III NRG Oncology/RTOG trials of radiotherapy (XRT) +/- chemotherpay in locally advanced (LA) head and neck cancer (HNC). Presented at 2015 ASCO Annual Meeting, 33:15 May 29-June 2, 2015:6003

134. Divi V,Harris J,Harari PM,Cooper J,McHugh J,Bell D,Sturgis E,Cmelak A, Suntharalingam M,Raben D,Kim H,Spencer S,LaramoreG,Trotti A,Foote RL, SCHULTZ CJ,Thorstad W,Zhang Q,Le QT,and Holsinger FC: Establishing quality indicators for neck dissection: Correlating the number of lymph nodes with oncologic outcomes, NRG Oncology/RTOG 9501-0234. Presented at ASCO Meeting 33:15 May 20, 2015:6011

135. Vassilakopoulou M, Won M, Curran W, Souhami L, Prados M, Langer C, Rimm D, Hanna J, Neumeister V, Mellan E, Diaz A, Atkins J, Brady L, SCHULTZ C, Howard S, Dicker A, Knisely J. BRCA1 Protein Expression Predicts Survival in Glioblastoma Multiformae (GBM) Patients From a RTOG Cohort. Int Jnl Rad Onc Biol Phys, 93,3:S141. November 2015.

136. Chang SM, Zhang P, Cairncross JG, Gilbert MR, Bahary J-P, Dolinskas C, Aldape KD, Chakravarti A, Schiff D, Jaeckie KA, Brown PD, Barger G, Werner-Wasik M, Shih HA, Brachman D, Penas-Prado M, Robins HA, Belanger K, SCHULTZ CJ, Mehta MP: Results of NRG Oncology/RTOG 9813- A Phase III Randomized Study of Radiation Therapy (RT) and Temozolomide (TMZ) versus RT and Nitrosourea (NU) therapy for Anaplastic Astrocytoma. Presented at Society of Neuro-Oncology (SNO) Nov 2015

137. Buckner J, Shaw E, Pugh S, Gilbert M, Barger G, Coons S, Ricci P, Bullard D, Brown P, Stelzer K, Brachman D, Sun J, SCHULTZ C, et al:IDH1 R132H mutations in NRG Oncology/RTOG 9802: Phase III study of radiation therapy (RT) alone vs. RT plus procarbazine, CCNU, vincristine (PCV) in patients with low grade glioma (LGG). Presented at Society of Neuro-Oncology (SNO) Nov 2015.

138. A. Dayal, M. L. Siker, S. Firat, J. A. Bovi, SCHULTZ CJ, W. M. Mueller, J. M. Connelly, and S. D. Rand: Clinical Significance of Updated MRI Simulation vs Immediate Post-Operative MRI for Radiation Treatment Planning in Patients with Glioblastoma: Changes in FLAIR Signal. (submitted to ASTRO 2016 96:2S) E103 Abs 2251

139. Yao M, MD, (Ed) Zhang Q, Woods C, Phuc Felix Nguyen-Tân, Rosenthal D, Garden A, Thorstad W, Pramila Rani Anne, SCHULTZ CJ, Caudell J, Filion EJ, Ridge JA, Jones CU, Kim HE, YomSS, Raben D, Bonner J, Machtay M, Harris J, Le OT: Intensity-Modulated Radiotherapy versus Three-Dimensional Conformal Radiotherapy in Head and Neck Squamous Cell Carcinoma: A Pooled Analysis of NRG Oncology/RTOG 0129 and 0522. (Submitted to ASTRO 2016 96:2S S116-S117 Abs#S260)

140. Erica H Bell, PhD, Joseph P McElroy, PhD, Jessica Fleming, PhD, Cynthia Timmers, PhD, Arup R Chakraborty, PhD, Andrea L Salavaggione, MD, Susan M Chang, MD, Edward G Shaw, MD, Kenneth D Aldape, MD, David G Brachman, MD, SCHULTZ CJ, MD, Helen A Shih, MD, Mark Curtis, MD, Grant K Hunter, MD, Albert D Murtha, MD, Peixin Zhang, PhD, Minhee Won, MA, Minesh P Mehta, MD, Arnab Chakravarti, MD1: A Mutation and Prognostic Biomarker Study in Grade II and III Gliomas Utilizing a Combined Cohort of NRG Oncology/RTOG 9802 and 9813. (Submitted to ASTRO 2016 96:2S S91 Abs #206)

141. Musaddiq Awan, Jill Barnholtz-Sloan, Haley Gittleman, Mitchell Machtay, Phuc Nguyen-Tan, David Rosenthal, SCHULTZ CJ, Bradley Huth, Wade Thorstad, Steven Frank, Harold Kim, Robert Foote, Miriam Lango, George Shenouda, Mohan Suntharalingam, Jonathan Harris, Qiang Zhang, Quynh-Thu Le, Min Yao. Development of Laryngeal Cancer Nomograms from Pooled Data of Two Trials of Concurrent Chemoradiation: NRG Oncology RTOG 0129 and RTOG 0522. Presented at ASTRO 2017, San Diego CA 99:2S, S45-S46 Abs #97

142. Guignard VM, Kelm SE, Gillingham B, Firat SY, Prah D, SCHULTZ C, Dayal A, Connelly J, Mueller W, Bovi JA, Siker ML. Pulsed Reduced Dose Rate Re-Irradiation (PRDR) Using Modulated Arc (mARC) IMRT for Recurrent Gliomas: Initial Clinical Outcomes of a Novel Technique. Oral presentation at ARS Annual Meeting May 2018.

143. Kelm SE, Guignard VM, Botros ME, Gillingham BT, Bovi JA, SCHULTZ CJ, Connelly J, Siker ML. Repeat Whole Brain Radiation Therapy Using a Pulsed Reduced Dose Rate Technique. Oral Presentation at ARS Annual Meeting May 2018.

1. Module 1: Primary malignant gliomas, Grand Round Series, CME Consultant, Medical Communications Media, 2004

2. Module 2: Brain metastasis, Grand Round Series, CME Consultant, Medical Communications Media, 2004